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Chapter 1 - Introduction 
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1.1 Introduction to bioanalysis and the pharmaceutical industry 
Every year pharmaceutical companies spend millions of pounds on R&D to 
assess and develop potential new compounds hoping for the latest blockbuster 
drug that will help treat a disease and potentially bring them a healthy return on 
their investment.   
 
Ten years ago, Edwards predicted a revolution for therapeutic peptides [1].  
Since then, almost every pharmaceutical company has shifted some of their 
R&D of new chemical entities (NCEs) from being mainly focused on small 
molecules, to branching into the peptide market [2].  Peptides are important to 
the pharmaceutical and biotechnology industries due to their low toxicity and 
high potency, making them excellent drug candidates [3].  They can also be 
beneficial as biomarkers in disease [4], not to mention the fact that there are 
currently several therapeutic peptides with a market size of greater than $1 
billion [5]. 
 
In 2004, an important report into the strategic analysis of the therapeutic peptide 
market was conducted by Frost and Sullivan [6].  The findings showed there to 
be more than 40 peptides on the market, nearly 300 in early stage clinical trials 
and over 400 in advanced stage clinical trials [6, 7].  Since then this market has 
continued to grow, with 67 peptides available to market in 2007 [2], and was 
expecting double-digit growth between 2003 and 2010 [8]. 
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In this research, an important group of peptide compounds – the vasopressin 
family, in particular arginine-vasopressin – has been investigated.  This was 
performed in the context of biological analysis (bioanalysis) as used in the 
pharmaceutical and contract research (CRO) industries for new medicines as 
required by law [9-13]. 
 
Bioanalysis is the analysis of drugs and chemicals in biological materials in 
order to gain information about them, which will enable drug discovery and 
development [14].  The route by which this is done is often not direct or straight 
forward, as there are many challenges along the way [15].  This research details 
many of the challenges faced in developing and validating a bioanalytical 
method and how to potentially overcome them.  
 
The aim of bioanalysis is to assess the levels of a particular drug in biological 
fluid in different stages of the drug development process.  The stages encompass 
discovery, where thousands of compounds are screened and the disease 
mechanisms analysed and pre-clinical (sometimes referred to as toxicological), 
where the effects of the drug in the body are measured (toxicology and 
metabolism).  Once these stages have been assessed, application is submitted to 
the regulatory authority [9-11].  On approval, phase I, II and III trials commence 
dependent on the results of the previous stage.  Phase I comprises low levels of 
the drug being dosed into a small number of healthy volunteers [16].  Phase II 
uses patients to see if the drug can treat the disease [16].  Phase III is a much 
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larger scale study of patients, which also uses a placebo in some patients; it is 
randomised and controlled to ensure a high standard of data, which will then be 
sent for approval to the regulatory bodies [16].  After approval, doctors monitor 
side effects in patients [16].  It is the samples generated in these trials which will 
be analysed using methods such as the one developed and validated in this 
research to quantify the amount of drug in each of the samples.  
 
The process of bioanalysis starts with the target analyte which is used in the 
toxicological and clinical trials.  This is used to dose the subjects.  Samples of 
biological material are then taken at various intervals.  These can be blood, 
plasma, serum or urine, among others [17].  These samples are then cleaned, 
analysed and the amount of target analyte in each sample compared to that of 
standards of known concentrations.  To do this a method which is robust in the 
assessment of the analyte must be employed and to get a suitable method, a 
method development process of trials based on analyte characteristics is 
performed, optimized and then a final method is validated for use in the analysis 
of the target analyte. 
  
The target analyte in this work was a nonapeptide hormone called arginine-8-
vasopressin (AVP).  It is 1.1 kDa in size and comprises nine amino acids with a 
disulfide cysteine bridge.  It is being used as a model compound for basic 
peptides in the development of a bioanalytical assay to explore what benefits can 
be gained in bioanalytical method development by improving the assay.   
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AVP has many important roles in the body but its primary role was discovered 
20 years ago by Verney and Du Vigneaud as being responsible for the osmotic 
constancy of body water [18, 19].  The importance of AVP in the renal system is 
widely researched and documented [18, 20-21].  AVP works to facilitate the 
“reabsorption of solute-free water from the collecting duct of the kidney” [22].  
Further to this, patients with type 1 diabetes are resistant to the anti-diuretic 
effects of AVP; this is shown through them not being able to recruit aquaporin-2 
and subsequently impaired urine regulation ability. 
 
Secondary effects of AVP include its effects on the circulatory system [23-24], 
as a biomarker [25-26], and in psychological diseases [627-28].  Elevated AVP 
levels can be directly related to arterial pressure, cardiovascular surgery [20], 
chronic heart failure [29], hypertension and bradycardia [23]. 
 
As a biomarker for disease, AVP is quite generic and elevated levels can be seen 
in plasma in diseases such as alcoholism [30], potential tumours [25], diabetes 
[31] and when a subject is under psychological pain or distress [33].  In cerebral 
spinal fluid (CSF) it is seen in increased levels in patients with motor neurone 
disease [26].  Other important roles AVP plays are in myometrial contractions in 
human labour [32], in mood disorders [33], and in response to IVF 
superovulation treatments [34]. 
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The method for analysis most commonly used for AVP is immunoassay [35-38, 
33, 18, 25, 34] where the limits of detection are in the range 0.5-1 pg/mL 
plasma.  At present there is limited vasopressin research using LC-MS/MS as the 
primary method for quantitative analysis.  It is therefore of great interest to 
determine the limits of detection which can be reached and to determine whether 
these can compete with immunoassay statistics. 
 
Immuno-affinity techniques are commonly used as a method of analysing 
peptides in biological fluids, as they have the potential to be highly selective due 
to very specific antibody-antigen binding [36-38], and sensitive.  They require 
an antibody binding specifically to the target analyte or to sites on the molecule.  
These antibodies are generated in a host (animal) and it is this production of 
antibodies that is the time-limiting step in the process [17,39-40]. 
 
The advantages of immunoassay are that it is very sensitive, has a low limit of 
quantification [35-37, 33], does not rely too heavily on the characteristics of the 
analyte such as its ability to ionise or fluoresce [17], it can be automated to 
increase throughput, and it is generally very selective although it may not be 
able to differentiate between the analyte and a closely related metabolite [38].   
 
The disadvantages of immunoassay are the amount of time it takes to set up [17], 
which can take from four months to a year, the selectivity of the assay where 
cross-reactivity testing needs to be very thorough to ensure that metabolite and 
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parent are distinguishable, matrix effects can occur in urine due to pH 
differences and the presence of polycarboxylic acids [17].  There can also be 
problems with false negatives if there is too high a level of antigen present [17].   
 
In this work, the challenge was to investigate the levels of AVP that can be 
detected using state of the art quantitative mass spectrometric techniques, so that 
a method could be developed and validated suitable to analyse samples from 
pre-clinical and clinical trials. 
 
Mass spectrometry is an important tool in bioanalysis because it is a highly 
selective technique [4, 32] that relies on the mass of the target analyte and the 
number of charges it possesses, which is especially significant when using 
electrospray ionisation where multiply charged ions may be formed [41-43].  A 
major benefit of mass spectrometry is its ability to differentiate between similar 
metabolites and the analyte, sometimes not possible in immunoassay [17].  
However a major drawback is the limit of detection [35-38] that can be reached, 
especially at physiological levels, although this can be less of a problem for 
biomarkers such as AVP which has been shown to have elevated levels in 
disease states  [4, 44-46]. 
 
There are many challenges in bioanalysis [15, 47, 48] some of which stem from 
the complex procedure of removing analyte from the biological matrix, effects 
of the matrix on the target analyte [48], and the compliance with government 
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regulations [9-11].  In the quest for cleaner samples, preparation procedures such 
as protein precipitation and solid phase extraction can be used in conjunction 
with liquid chromatography mass spectrometry for the removal of impurities and 
to extract and concentrate the analyte, and thus improve limits of detection. 
 
In the cleaning of samples, matrix interferences need to be removed as these may 
interact with the analyte, causing inaccurate concentration readings, caused by 
enhancement or suppression of the detected signal.   Removing the analyte from 
a biological matrix can be a complicated process.  The main problem is 
removing the many proteins in plasma that may interfere with the analysis.  
Matrix effects are the suppression or enhancement of the detected analyte signal 
by components of the sample matrix, and are often compared by using pure 
standards in the presence and absence of biological matrix [49-59].  There are 
several ways to reduce matrix effects, the main one of which is to improve 
sample clean-up by using fractionation techniques [60-61]. 
 
1.2 Fractionation techniques  
Fractionation techniques are important in bioanalysis due to the nature of the 
matrices and sample complexity involved e.g. blood, urine, plasma, and the 
often low levels of analyte that need to be detected and quantified.  The most 
important factors are to isolate the analyte [62-64] and remove any interfering 
substances [17, 62, 64-65].  
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There are many stages in bioanalysis where fractionation techniques are 
employed.  These can range from the centrifugation of un-clotted blood to give 
plasma, through to sample preparation via column chromatography or ultra high 
performance liquid column chromatography (UHPLC).  The focus of the 
techniques applied in this work is on preparing plasma samples read for 
high/ultra high performance liquid chromatography-mass spectrometric analysis. 
 
Fractionation techniques are employed prior to quantitative analysis as the levels 
of interferents in the sample are frequently too high to be removed solely by an 
HPLC step.  This may be due to high levels of proteins in the sample [17,66-67] 
or the sample may need to be concentrated to improve limits of detection [65, 
68].  The most common techniques employed in bioanalysis are protein 
precipitation, liquid-liquid extraction and solid phase extraction [17, 64], each of 
which have different benefits, drawbacks and suit abilities for different types of 
analytes. 
 
1.2.1 Protein precipitation 
Protein precipitation (PP) is the simplest sample preparation technique utilised, 
as it focuses only on the removal of proteins from plasma.  Proteins need to be 
removed from the sample due to their incompatibility with subsequent 
separation techniques such as HPLC [17, 64, 67] There are a variety of ways to 
remove proteins from a sample using heat, salts, organic acids or solvents [17, 
64, 67].   
Page | - 18 -  
 
 
The most commonly used method for protein removal is to use solvents 
(organic) due to their being readily available, inexpensive and the technique 
being simple [66], they are also volatile and so can be readily removed from the 
sample if necessary.  When organic solvents are added to plasma (at least 1:3 
plasma: solvent) [17,66, 69], the di-electric constant of the solution is lowered, 
which results in an increase in the electrostatic interactions between protein 
molecules [17]. The organic solvent molecules can also displace water 
molecules, which can increase the electrostatic interactions and further the 
protein aggregation [17].  The ultimate aim in PP is to denature the proteins so 
that they precipitate out of solution and can be removed by centrifugation 
(>3000g) [17,69-71].   
 
The benefits of this technique lie in the fact that it can be easily automated in a 
96 well plate format, resulting in it being cheap and allowing high sample 
throughput.  
 
Figure 1 – Protein precipitation procedure 
 
 
 
Aliquot plasma 
Add precipitation solution 
Mix and centrifuge 
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Although PP is often the method of choice and a primary step in bioanalytical 
method development, it only removes protein and so the sample may require 
further clean up e.g. solvent treatment does not remove phospholipids and these 
may interfere with detection [72-73] and cause matrix effects [65, 68, 72-73].  
Slightly more complex methods such as liquid-liquid extraction using analyte 
properties to achieve a more thorough clean up may be preferable. 
 
 
Transfer supernatant 
Dilute with solvent 
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1.2.2 Liquid-liquid extraction 
Liquid-liquid extraction (LLE) is a separation technique based on the use of two 
immiscible solvents [64] (generally an aqueous and an organic), and is 
dependent on polarity and the solubility of the analyte in each of the solvents 
[66].  The main influences in LLE are the pH at which the analyte is un-ionized 
[64], as this technique is generally not suitable for isolation of charged analytes 
[66], the volume of solvents used, which should be at least five times the 
aqueous sample volume and well mixed [17], and the compatibility of the 
analyte with each of the phases –e.g. non-polar analytes extract best into non-
polar solvents [67].  If the analyte moves into the organic layer, the solvent may 
be suitable to be evaporated and the sample reconstituted in a solvent of choice, 
depending on the type analysis required (figure 2). 
 
Figure 2 - Liquid-liquid extraction 
 
A: sample in plasma matrix, B: addition of extraction solvent, C: mixing phases 
followed by phase separation, D: centrifugation, E: removal of supernatant, F: 
evaporation and reconstitution in appropriate solvent. 
A C F
D 
B D E 
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Although LLE may benefit sample clean up as it is not just based on removing 
proteins but on the analyte‟s chemical characteristics, however it is unsuitable 
for the analysis of polar or ionized species..  Other techniques such as solid 
phase extraction (SPE) can offer improved clean-up and has up to 50 times the 
separating power of a simple LLE [62]. 
 
1.2.3 Solid phase extraction (SPE) 
SPE uses a solid support, in the form of a stationary phase , which the analyte 
can interact with and bind to selectively.  The process involves steps to prime the 
solid support and equilibrate it, so that it is prepared for the sample.  The sample 
is then loaded and passes through the SPE column, where the analyte interacts 
with the sorbent.  Elution of interferent species takes place and then separately 
of the analyte itself with specifically tailored washes.  After elution, the sample 
is evaporated and reconstituted in a medium appropriate for LC-MS/MS 
analysis.  A diagram of the processes in SPE is given in figure 3. 
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Figure 3 - SPE 
 
 
 
SPE gained popularity in bioanalysis  in the early 80s as a replacement for LLE 
as it is compatible with a larger variety of compounds [62,64, 66].  The main 
reason for this was that it is not only compatible with polar compounds but also 
zwitterions such as amino acids, as there are many different stationary phases 
which can be used [66].  The mechanism of SPE depends on using a 
chromatographic solid phase in the form of a solid sorbent and a mobile phase.  
The mechanism for SPE is dependent on the type of stationary phase used and 
this determines which mobile phase(s) can be used.  The two main mechanisms 
are reversed phase and ion exchange, although due to the polar nature of the 
analytes typical of bioanalysis [68, 74], mixed mode SPE is often used. 
 
A B C 
C 
D 
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Reversed phase (RP) SPE generally uses a C18 or C8 type packing.  However 
there are polymer sorbents such as polystyrene di-vinyl benzene (Waters Oasis 
HLB) [6875-77] which have become increasingly popular.  The structure of this 
polymer can be seen in figure 4.  This method development, as previously 
mentioned takes place in the form of a gradient profile, where different ratios of 
solvent are trialed to determine the best sample clean up (Figure 3, c) and 
recovery  (Figure 3, d). 
 
Figure 4 –HLB reversed phase sorbent structure, adapted from [18] 
 
Mixed mode SPE is an important technique that utilises different interactions in 
the same stationary phase.  An example of this is Waters Oasis mixed mode 
weak cation exchange sorbents for very basic compounds (WCX).  When using 
an ion exchange sorbent it is important that the sample is loaded at the correct 
pH for the analyte to be ionized [17,68,75,78] and subsequently interact with the 
charged species on the stationary phase [75,79].  Once the analyte is bound, it 
may be transferred between the charged groups and benzene ring using the ionic 
and RP interactions to assist sample clean up.  The stationary phase structure for 
this mixed mode sorbent is given in figure 5. 
Page | - 24 -  
 
 
Figure 5-  Waters Oasis WCX sorbent chemistry, adapted from [18] 
 
 
Once the process of removing interferences from the biological sample has been 
completed using primary separation techniques, it is then introduced to a 
secondary more advanced separation technique such as HPLC, interfaced with a 
detector for quantification. 
 
1.3 Separation techniques 
High performance liquid chromatography (HPLC) is an analytical 
chromatographic technique which separates molecules based on their physico-
chemical characteristics [63,80] using a stationary phase for which analytes have 
different affinities to [81-82].  It works at high pressures of 6000 psi and modern 
ultra high performance liquid chromatography can work at up to 15000 psi [83].  
This means that smaller particles can be used in the stationary phase along with 
higher flow rates, reducing sample analysis time. 
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1.3.1 The HPLC system  
The principle components of an HPLC system are the solvent reservoir, the 
pump(s), injection valve, column (and column oven), the detector and recorder.  
A schematic is given in figure 6. 
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Figure 6 – Schematic of an HPLC system  
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The solvent reservoirs not shown on diagram supply the mobile phases and needle 
washes.  The mobile phases are used to control the elution of analyte from the 
column [69,83-84].  The washes are used to clean the needle and loop after each 
injection in order to minimise sample carryover [17,84].   
 
The pumps used in HPLC need to be „pulse-free‟ and to give a steady continuous 
flow at high pressures otherwise a steady signal will not be detected.  This can be 
done using dual-piston pumps [66].  In UHPLC, two serial flow pumps are used and 
enable mixing at high pressure. [85-86]   
 
The column itself consists typically of a stainless steel body which has a polished 
interior filled with stationary phase [69,87,88].  The internal diameter (i.d) of an 
analytical HPLC column is generally 4.6 mm and the length 25 cm [88].  In UHPLC 
this is typically reduced to an i.d of 2.1 mm and length 5 cm.  The diameter of the 
packing material particles is especially important.  This is because the smaller the 
particles, the tighter the packing can be, resulting in more particles in a small space 
[87] and the more regular the path of the analyte through the column [reduces peak 
broadening – van Demeter].  This means that there is a larger surface area for the 
sample to interact with but also small gaps between particles through which the 
phase flows, causing higher back pressures [87].  This is especially important for 
UHPLC columns where the particles are sub 2 m in size. The column oven allows 
the temperature can be controlled and varied as required. 
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The type of detector used in quantitative bioanalysis is most commonly a mass 
spectrometer as it is sensitive and selective [75,89].  This is discussed in more detail 
later in this chapter, once the fundamental principles of chromatographic separations 
have been explored. 
1.3.2 Chromatography principles  
Chromatography is the movement of mobile phase over a stationary phase where 
analytes are separated based on their differential affinities for the stationary and 
mobile phases, causing retention and separation [90]. There are five main types of 
molecular forces which govern the interactions between the analyte and the phases 
[91].  These are 1, Van der Waals forces which occur between non-polar molecules 
[92-93]; 2, dipole-dipole interactions [94] which result from a distorted electron 
cloud; 3, hydrogen bonds between proton donors and acceptors [95]; 4, dielectric 
and finally 5, electrostatic interactions [91] which are charged species interactions 
e.g. ion-ion interactions [90]. 
 
 
1.3.2.a  Distribution 
The first important factor in chromatography is the distribution of analyte between 
stationary and mobile phase [96].  This can be described as the concentration of 
analyte in the stationary phase divided by the concentration of analyte in the mobile 
phase [17, 84].  The equation for this is k=cs/cm where the distribution co-efficient is 
referred to as k and the concentration in the stationary and mobile phases cs and cm 
respectively.  The value of k is important in chromatography as a large value of k 
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reflects a high proportion of analyte in the stationary phase compared to the mobile 
phase, thus retention is greater and elution slower.  A small value of k reflects a 
small amount of analyte in the stationary phase and a larger amount in the mobile 
phase resulting in less retention and fast elution from the column [84]. 
 
1.3.2.b  Retention  
The extent to which an analyte is retained on a column is called its retention and it is 
determined by the amount of time the analyte takes from injection to it leaving the 
column and being detected.  This is the retention time tR.  The rate at which the 
sample travels from injector to detector is described by the retention (or capacity) 
factor k‟ [64,87-88,97].  Calculation of k‟ for all analytes is the retention time minus 
the time taken for the mobile phase to pass through the column (tm), divided by the 
time taken for the mobile phase to pass though the column (tm).  The equation is k‟ = 
(tR-tm)/tm. 
 
1.3.2.c  Selectivity 
Separation of components of a mixture is important in bioanalysis due to the 
complex matrices which are analysed.  Therefore the analytes need to be retained 
selectively so that they do not co-elute [88].  The selectivity factor (α) is dependent 
on the retention factor k‟ of each analyte (a and b) as α = k‟a / k‟b . 
 
 
 
Page |  
 
30 
1.3.2.d  Column efficiency 
The efficiency of the column is an important consideration as in chromatography 
there is a needs for chromatographic peaks which are sharp, separate and resolved 
with as short a run time as possible so as to maximize throughput.  There are two 
models for calculating column efficiency; the first model based on theoretical plates 
has by some been replaced by the rate theory [90, 98].   
 
1.3.2.e  Plate theory 
The theoretical plate model was set out by Nobel laureates Martin and Synge in 
1954 [90,98].  The idea is that the column is made up of a series of theoretical plates 
[82,90] and at each of these plates there is a phase distribution as described in eqn 1.  
As the mobile phase flows through the column, so does the analyte, which is in the 
mobile phase and so flows from one plate to the next [17].  An important factor in 
plate efficiency is plate height which needs to be as small as possible.  One way of 
lowering it is to use smaller particles of stationary phase [90].  Height equivalent to 
the theoretical plate (HETP) can be calculated using equation 1; this equation has 
two unknowns, the HETP and the number of plates.  The number of theoretical 
plates [90,98] can be calculated from equation 2.  The modern version of this theory 
is the rate theory and it forms the basis of the van Deemterequation, which is given 
in equation 3. 
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Eqn 1:   HETP = column length / number theoretical plates  
Eqn 2:   number of theoretical plates = 5.55 x (retention time)
2 
       
(peak width at half height)
2
 
 
Eqn 3:   HETP = A + B / µ + Cµ 
 
1.3.2.f  Rate theory  
The basic principles of rate theory are that it takes different factors into 
consideration such as the time it takes for the partition equilibrium of the analyte 
between mobile and stationary phases [90].  It is described by the van 
Deemterequation (3).  The factors affecting the HETP include the consideration of 
eddy diffusion [90,99-103] (A term in equation 3), where molecules may not all take 
the same route through the stationary phase particles [90].  Longitudinal diffusion 
[90,99-103] is described by the B term in equation 3 and reflects the speed (linear 
velocity) at which the analyte flows through the column.  This is important as it can 
impact on peaks becoming wide and diffusing at the edges of the peak (band 
broadening), which is caused when the flow rate is too slow and the analyte itself 
does not form a sharp peak but a broad one.  The barrier to mass transfer is the C 
term in equation 3.  It is of importance because when the velocity of the mobile 
phase is too high, but the analyte has a high affinity for the stationary phase, the 
analyte in the mobile phase will quickly pass through the column due to the flow 
rate.  If there is a greater analyte interaction with the stationary phase, it will take 
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longer to elute the analyte which can result in subsequently broad peaks [90,101-
103].  The linear velocity of the mobile phase in equation 3 is µ [90]. 
 
A van Deemterplot can be used to describe the relationship between plate height and 
mobile phase flow rate as illustrated in figure 7. This shows the minimum plate 
height and thus the optimum velocity of the mobile phase.   
Figure 7- van Deemterplot, adapted from [90]  
 
 
1.3.2.g  Resolution 
The resolution is a measure of how well two peaks separate [17].  The separation of 
two peaks can be described in terms of their resolution as given in equation 5, where 
tR is the retention time, w the peak width at base and a and b analytes in the mixture.  
Baseline resolution of two peaks occurs when R≥1.5. 
 
Eqn 5:      
ba
rbra
WW
tt
R
2
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The resolution can be influenced by the number of theoretical plates in the column 
(N), the selectivity factor and the retention factor of the analytes to be separated 
[94,103].  These factors can be combined to give equation 6.  In this equation there 
is the retention factor (k‟) which can be altered by changing mobile phase 
conditions, the number of theoretical plates (N), which can be increased by 
lengthening the column or reducing the stationary phase particle size, and also the 
selectivity factor (α) which can be altered by changing mobile or stationary phases 
and column temperature [101].  Other changes that can be made to improve the 
resolution include: changing the mobile phase flow rate, using a gradient elution and 
ensuring the packing and stationary phase particle size are uniform [82]. 
 
Eqn 6:  R=(√N/4){(a-1)/a}{(1+k‟b)/k‟b} 
 
1.3.3 Separation mechanisms 
There are many different types of chromatography used in HPLC. The chemistries 
can be similar to some of those exploited in SPE, such as reversed phase or ion 
exchange, however a gradient elution can be applied which can allow for faster 
analysis for a wide variety of compounds with different properties.  The main 
mechanisms utilized in HPLC are adsorption in normal phase (NP) chromatography, 
and partitition in reversed phase chromatography (RP) and hydrophilic interaction 
liquid  chromatography (HILIC). 
 
Adsorption in NP chromatography works by utlising the adsorptive properties of the 
stationary phase (often silica); suggested mechanisms for this type of 
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chromatography are based on analyte molecules displacing solvent molecules that 
are bound to the stationary phase, and also sorption of the analyte molecules onto the 
layer of solvent molecules which are adsorbed onto the stationary phase, without any 
kind of displacement [17,84,101, 103].  Key interactions in the mechanism of NP 
chromatography include dipole-dipole and dipole induced dipole interactions 
[94,104-105] as well as hydrogen bonding.  In NP chromatography, the stationary 
phase is polar, the mobile phase is non-polar and the least polar components of the 
sample mixture are eluted first [84]. 
 
Reversed-phase chromatography is common in bioanalysis due to its robustness and 
reproducibility.  A common mechanism for some reversed-phase systems is 
partitioning which works by hydrophobic interaction [84].  The stationary phase is 
made up of carbon chains on a silica support, the more carbon atoms in the chain, 
the better the retention of hydrophobic analytes as there is increasing hydrophobicity 
of the stationary phase [103,106].  Subsequently a common chemistry used is the 
C18.  In reversed-phase chromatography, the stationary phase is non-polar, the 
mobile phase polar and subsequently the most polar components are eluted first [84]. 
 
HILIC is a separation technique which uses a hydrophilic stationary phase.  There 
are many different types of stationary phases for HILIC such as zwitterionic phases, 
however this section focuses on using bare silica due to its reproducibility [103].  
The stationary phase is saturated with a layer of water molecules and these surround 
the silica [103].  The main proportion of the mobile phase is an organic solvent, 
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typically acetonitrile.  There are many aspects to the mechanisms that occur in 
HILIC, starting with the partitioning, where the analyte can move between the 
organic phase and water phase which surrounds the silica [103], where the analyte is 
retained until the amount of water in the mobile phase exceeds the level required to 
saturate the silica.  Another important factor is the Coulombic interactions and 
hydrogen bonding resulting from the stationary phase, and the water molecules, 
which are bound to the phase [107-109]. 
 
Benefits of HILIC include increased ESI-MS sensitivity due to the high organic 
solvent [17].  The elution order is in terms of analyte hydrophilicity, with the least 
hydrophilic analytes eluting first. 
 
A detector is required to measure the signal produced by the analyte in order to 
quantify it.  The types of detector can be varied, but the most common type used 
today is a mass spectrometer. 
 
There are many different types of mass spectrometers, however the type often used 
in quantitative bioanalysis is a triple quadrupole [77, 110-111, 75].  This is due to 
the selective modes of operation such as multiple reaction monitoring (MRM) which 
make efficient use of the duty cycle by focusing on selected ions, therefore 
increasing sensitivity [17,112].    
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1.4 Mass Spectrometry 
Mass spectrometry has been a long established technique in the analytical world 
since the first mass spectrometer was developed in 1897 by J.J. Thomson who used 
it to measure anode and cathode rays [113]. Since this date, a range of significant 
developments have been made such as the time of flight mass analyser by W. 
Stephens in 1946, and the electrospray ionisation source in 1969 by Dole [114] 
which, although not developed for MS was further developed and utlised for MS by 
Fenn in 1984 [115].  Other developments include the quadrupole and quadrupole ion 
trap [116] in 1953 by W. Paul, the development of collision induced dissociation 
(CID) in 1968 [117] by K.R. Jennings and F.W. McLafferty, and tandem mass 
spectrometry in 1966 by J.H. Futrell [118].  Other significant developments in terms 
of how we practice MS today include the matrix assisted laser desorption/ionisation 
(MALDI) source by F. Hillenkamp and M. Karas in 1985 and Tanaka (1988), and 
the Orbitrap in 1999 by A. Makarov. 
 
A further improvement was the coupling of liquid chromatography (LC) with mass 
spectrometry.  This enabled higher throughput and increased efficiency in sample 
analysis [17].  This however meant that the reagents for LC must be compatible with 
mass spectrometry and vice versa. 
 
As the focus of this thesis is the analysis of biomolecules in biological fluids, it is 
important to examine the most commonly used approaches for such applications.  
The most commonly used type of mass spectrometer is the quadrupole; this is 
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because they are highly sensitive and can be used to focus on just one or a few 
species at a time.  The technique of MRM has been applied to small molecules for 
many years, and more recently to peptides and proteins.  The quantitative analysis of 
peptides and proteins was traditionally the focus of immuno-affinity techniques, 
such as ELISA [17] but has been of interest to mass spectrometrists due to the 
benefits which can be gained from using mass spectrometry over immuno-affinity 
analysis, such as efficiency, sample throughput, selectivity, faster set-up times, 
lower costs and the structural information, not available from immuno-affinity 
techniques. 
 
Immuno-affinity techniques have been used as an analytical technique since the mid 
1950s [17] due to the low levels of quantification that can be reached.  They rely on 
production of an antibody.  This is a costly and time consuming process.  The 
alternative of using LC-MS/MS has the potential to reach the same detection limits 
as immuno-affinity [119].   
 
The mass spectrometer 
A mass spectrometer is made up of four main parts.  These are the sample inlet, the 
ion source, the analyser and the detector, all of which have a different design 
dependent on the application; a general schematic is given in figure 8.  In 
bioanalysis, the samples generally come from an HPLC system and therefore are 
already in solution in the mobile phase.  This thus needs to be compatible with the 
ion source. 
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Figure 8 – general schematic of a mass spectrometer 
 
 
Commonly used ion sources in bioanalysis include electrospray (ESI) and 
atmospheric pressure chemical ionisation (APCI). 
 
1.4.1 Electrospray ionisation 
ESI was primarily developed as a technique independent of mass spectrometry.  It 
was first implemented in 1968 by Dole, for polymer analysis [120].  Its potential was 
realised by Fenn, Yamashita and Alexandrov for use with mass spectrometry in 
1984 [121-125].  The source was then further developed [126] to give the typical 
format we work with today.   
 
In ESI, the ions in solution travel down a capillary which has a voltage of several 
kilovolts applied to it [127].  It can operate without heat, although most modern 
systems such as the API 5000 (figure 9 - Applied Biosystems, Canada) and TSQ 
Quantum Ultra QQQ (ThermoFisher Scientific, UK) use heat.  The result of the 
TurboIonSpray is a fine spray of charged droplets where there can be multiple 
charges and the charge on these droplets is determined by the polarity of the electric 
field [17].    
sample inlet ion source mass 
analyser 
detector 
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Figure 9 – API 5000 Triple quadrupole mass spectromter with TISP source 
[128] 
 
 
Figure 10 – ESI model adapted from [19] 
 
 
 
 
 
 
 
As the mobile phase containing the analyte passes through the capillary, the charge 
causes a spray effect due to the voltage on the capillary with a Taylor cone at the end 
of the capillary where a jet of liquid is emitted at a threshold voltage [129] and this 
results in the formation of charged droplets, which occurs when the droplets leave 
3-6 kV 
MOBILE PHASE 
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the charged tip.  They travel into the first vacuum stage, driven by an electric field.  
A nebulization gas such as nitrogen is often used to help aid droplet formation and 
the solvent evaporates until the Raleigh [130] limit is reached.  At this point, the 
drop is unstable [120] and breaks, in a process described as columbic fission 
(essentially the repulsive forces between the charges become greater than the surface 
tension on the droplet) [128].   
 
In ESI there are two different theories to the mechanism.  However it has been 
suggested that it doesn‟t really matter which one is correct as they both lead to the 
same result [129].  The process of ion evaporation in which the ion leaves the 
droplet (figure 11A) is one of the processes by which desolvated ions are proposed 
to be formed.  Alternatively a small droplet containing an ion leaves the larger 
droplet (figure 11B).  These are more technically referred to as the ion evaporation 
model [131] and the charge residue model [132].  In the ion evaporation model, the 
field strength at a droplet‟s surface becomes strong enough, when a small enough 
droplet size is reached, to encourage an ion to leave the droplet [131].  In the charge 
residue module, it is suggested that there are many steps of fission which gradually 
cause the droplet to get smaller and smaller until there is only one ion left.   The ions 
are then accelerated into the mass analyser by application of an electric field. 
 
Figure 11 – a) ion evaporation model, the ion leaves the droplet b) The charge 
residue model, where a small droplet leaves the larger one adapted from [129] 
B 
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1.4.2 Atmospheric pressure chemical ionisation (APCI) 
APCI is another technique which can be used in combination with LC to ionise 
biomolecules; a schematic is given in Figure 12.  It works by using a heated 
nebulizer [17].   The nebulizer gas makes heated droplets which rebound off the hot 
surface of the capillary and vapourise in a manner referred to by Covey [129] as 
nucleate boiling, by conductive heat transfer via the surface of the liquid.  At optimal 
conditions (when the temperature in the capillary is hot enough) the Leidenfrost 
effect occurs.  This is when a film layer builds up between the solvent and the walls 
of the capillary and subsequently the droplets rebound before impact on the capillary 
walls. As the droplets flow out of the capillary, the corona discharge needle which is 
highly charged causes solvent molecules to be ionized.  These gaseous solvent ions 
react with neutral analyte molecules to give charged species (ions), which are then 
accelerated into the mass spectrometer [133-134].  Although used in bioanalysis, this 
technique does always not provide as much sensitivity as ESI [17].   
 
Figure 12 – APCI schematic, adapted from [129] 
A 
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1.4.3 Mass analyser 
Mass analysers provide the selectivity element for mass spectrometry; different 
styles of mass analyser have different benefits e.g. high resolution, fast scan times, 
low levels of detection.  The mass analyser used in an experiment depends on what 
results are required.  Quadrupoles are the most appropriate mass analyser for use in 
quantitative mass spectrometry, due to their selectivity as a mass filter in SIM and 
MRM modes rather than scanning mode.  The quadrupole mass analyser is not 
suitable for all mass spectrometric applications, due to the duty cycle being poorer in 
full scan mode (i.e. to scan a range of different m/z) as it only has a short amount of 
time to transmit each ion, whereas if it was to focus on just one or a few specific m/z 
species, then it acquires those data for a greater proportion of the total cycle time.   
 
 
Quadrupole mass analyser 
A quadrupole is composed of four identical rods, ideally hyperbolic in cross section  
but often cylindrical due to ease of manufacture [17], arranged as in figure 6.  The 
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pairs are electrically connected so that the two opposite rods have the same charge as 
shown in figure 13 negative for the vertical rods and positive for the horizontal rods. 
 
Figure 13 – quadrupole rods 
 
Pairs of rods, of opposite polarities, have an RF voltage 180º out of phase from each 
other.  This RF voltage (radio frequency) is fixed at 816 kHz and establishes 
harmonic ion trajectories.   The rods also have a direct current applied.   
In order for ions to pass through the quadrupole, they need to have the correct 
trajectory.  This is determined by the RF and DC voltages, figure 15 shows the 
optimum transmission settings.  To understand this more fully, it is easiest to look at 
how light and heavy ions move when subjected to electric fields.  If a light ion enters 
the quadrupole with a positive charge, it will be drawn towards the negative rods, the 
rods are constantly and quickly switching polarities and the ion therefore moves 
towards whichever rods have negative charge.  Small ions can change direction 
quickly and therefore avoids collision with the rods as is shown in figure 14A where 
the low mass ions are transmitted.  Figure 14 illustrates this and also the ions filtered 
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by the positive rods (B) these combine to give the transmission diagram c where the 
window is 1 m/z (unit resolution) 
 
Figure 14 – Low mass filter transmission diagram for negative rods (A) and 
High mass filter transmission diagram for positive rods (B) and a combined 
diagram (C) 
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Figure 15– stable ion trajectories adapted from [135] 
 
 
 
Figure 16 – cross section of a single quadrupole showing a stable trajectory of 
ions [26] 
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Figure 15 also illustrates that in RF-only mode, where there is no dc voltage applied, 
all ions are transmitted.  This effect is used on some mass spectrometers as an ion 
focusing device. Figure 16 shows a quadrupole in which the dc and RF voltages 
have been optimized for an ion with medium m/z shown in black.   
 
Although single quadrupole instruments are available, they have mostly been 
replaced by more selective instruments such as triple quadrupoles.  These are the 
most commonly used instruments for quantitative bioanalysis [17].  They comprise a 
single quadrupole (Q1 and Q3) as mass filters with a collision cell in between (figure 
17). 
 
Figure 17 – triple quadrupole (QQQ) layout 
 
 
 
Multiple reaction monitoring mode (MRM), is a technique where multiple sets of 
ions can be analysed in Q1 and Q3 and still optimize the duty cycle.  In this case, 
there are two transitions with a similar m/z can influence each other‟s spectra; this is 
referred to as cross-talk.  Cross talk can be minimized by implementing a time gap 
single quadrupole 
 
single quadrupole collision cell 
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between analyte scans allowing for the collision cell to clear prior to the next 
transition being analysed.  
 
1.4.4 Collision cell 
The collision cell also consists of four (or sometimes six or eight) rods contained in 
a vacuum.  Ions are accelerated into the collision cell, thus gaining some additional 
kinetic energy.  This kinetic energy is converted into internal (vibrational) E when 
the accelerated ions subsequently collide in the collision cell with molecules of a 
neutral gas, typically nitrogen or argon and fragmentation results. This is collision 
induced dissociation.   
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Figure 18- Cross section of a triple quadrupole instrument adapted from [26] 
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1.4.5 Peptide fragmentation 
Peptides are chains of amino acids joined by peptide bonds (amide linkages) (figure 
19).  The weakest bond in the peptide backbone is the amide bond and this is 
generally the first bond to break when a peptide ion is subjected to CID.   
 
Figure 19 – tetrapeptide (four amino acids joined by peptide bonds) 
 
 
The mechanism of how peptide ions fragment is based on the mobile proton 
mechanism as proposed by Gaskell and Wysocki [135].  The two most common 
peptide fragments in positive ion mode CID spectra are b and y ions (figure 20).  
The formation of b and y ions by the mobile proton mechanism is summarised in 
figure 20.  Figure 21, outlines the two routes which are taken in peptide bond 
fragmentation from singly protonated peptide molecules to produce b and y ions. 
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Figure 20 - the fragmentation of peptides to give b and y ions, adapted 
from [136] 
 
Figure 21 – the mobile proton theory of peptide fragmentation, 
adapted from [136] 
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1.5 High field asymmetric waveform ion mobility spectrometry (FAIMS) 
Increasingly, quantitative bioanalytical assays are exploring new ways to improve 
their sensitivity [137].  The challenge with many signal-enhancing techniques is to 
achieve this without an increase in the background noise.  The TSQ Quantum Ultra 
triple quadrupole (QQQ) mass spectrometer can be used in conjunction with FAIMS 
technology as a means of enhancing sensitivity.  This technology is designed to 
improve the signal-to-noise ratio [38] by reducing the chemical and endogenous 
matrix component noise [37,39] whilst transmitting analyte ions.  This approach has 
shown significant benefits in bioanalytical assays such as improved signal-to-noise 
ratio, improved limits of quantification and assay robustness [140-142].  Other 
benefits of FAIMS include its ion focusing mechanism [143] that offers high 
sensitivity and the fact that it operates at atmospheric pressure and ambient 
temperature, which offers ease of operation [143].  FAIMS also has the potential 
benefit of being able to separate isomers such as leucine and isoleucine [144-145] 
 
FAIMS can reduce chemical and endogenous background noise [146] by adding an 
extra selectivity factor.  In FAIMS, ions are separated by their differential ion 
mobility as they pass through low and high electric fields.  The selection of 
transmitted ions is regulated by the compensation voltage, which is compound 
dependent [146-147], and thus offers a means of separating analyte from background 
ions, thereby improving detection and reducing noise. 
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A diagram of the FAIMS interface is given in figure 22.  Part A is the ESI source 
where the ions are formed.  Part B is the FAIMS cell.  The cell is made up of two 
concentric cylinders [143] (figure 23), which are electrodes that have a voltage 
applied to them (figure 3). 
 
Figure 22- FAIMS interface, adapted from [13] 
 
 
The FAIMS cell is filled with a mixture of helium and nitrogen gas.  As the ions 
pass into the cell, dispersion (DV) and compensation (CV) voltages are applied to 
the inner electrode.  Ions oscillate due to a combination of these voltages applied in a 
waveform.  The DV is set at a constant value and determines the magnitude of the 
waveform [148].  The CV alternates between a high field (kh) for one unit of time 
and then a low field (k) of opposite polarity [149] for two units of time to give an 
asymmetric waveform type function [149] (figure 24).   
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The CV is the selectivity factor, and affects the trajectory of ions through the 
FAIMS cell in different ways dependent on their mobility.  Subsequently only ions 
for which the CV is optimised will have a stable trajectory through the FAIMS cell.  
This is best described in figure 3, where the movement of ions through the electrode 
is determined by the field and its effect on the mobility of the ions. Selectivity is 
achieved because the ions behave differently in the high and low fields [150-151] 
 
Figure 23- FAIMS cell electrodes 
 
 
 
 
 
 
 
Figure 24- the asymmetric waveform, adapted from [149] 
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Bioanalytical assays involve the steps of fractionation, separation and quantification 
techniques.  The importance of using mass spectrometry to quantification is that the 
selectivity which can be used for MRM analysis.  Important additions to the method 
can include an internal standard, which should behave in the same way as the 
analyte.  This can be used as an analyte to internal standard ratio.   
 
1.6 Internal standards for quantitative analysis 
Internal standards are important in mass spectrometry as they are designed to mimic 
the behavior of the analyte and thus account for any variation in sample extraction 
and ionization efficiencies of individual samples.    Commonly, either a structural 
analogue of the analyte or a stable isotope-labeled internal standard is used.  
Analogue internal standards are used because of their structural similarity to the 
analyte, although there are likely to be differences in LC retention time and this may 
not account for ionisation variability [17] due to differences in co-eluting matrix 
components. 
 
A stable isotope-labeled internal standard is the preferred choice and the most 
suitable isotopes are 
13
C and 
15
N; although 
2
H can be used, it exhibits some 
additional effects due to the size of the deuterium over hydrogen which give it 
different special characteristics and subsequently a slightly earlier elution time when 
assessed by RP-LC.  However as this can be marginal it is only important that the 
deuteriums are not able to hydrogen exchange with the solvents. 
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1.7 Detector response comparisons in quantitative analysis 
In assessing a suitable instrument to give the lowest limits of detection and best 
performance, the best way place to start is without involving matrix effects and 
simply preparing standards of the analyte at known concentrations and assessing the 
response on different mass spectrometers using the same conditions. 
 
The techniques detailed in fractionation, separation and quantification help to 
improve the selectivity and sensitivity of an assay.  They support the fundamental 
foundations of regulated bioanalysis, its guidelines and its regulations and this is the 
important aspect of bioanalysis is the regulations and compliance with those 
regulations.  The regulations set out by government agencies such as the food and 
drug administration (FDA) in the USA, the medicines and health regulatory 
authority (MHRA) in the UK and the European medicines agency (EMEA) in the 
EU [9-11].  These, among others are crucial to the bioanalyst in knowing what is 
required of the work they perform.  These guidelines [9-11,152-153] provide the 
structure, and they ensure that the work carried out on new chemical entities (NCEs) 
is of a standard to justify this drug reaching market [12, 13].  In order to fulfil these 
guidelines, a method must be deemed “validated” or to have fulfilled specific 
validation criteria set out by regulatory bodies.  These criteria show that the assay is 
robust and suitable for use.  It is achieved by analysing a set of quantitation 
standards and AVP spiked frozen plasma standards.  Several of these analyses can 
be performed, generally on different days, to show repeatability in the form of inter-
day and intra-day precision and accuracy. 
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1.8 Validation 
A bioanalytical method validation is a series of experiments designed to test an 
assay and see if it is suitable for use in the quantitative analysis of clinical/ pre-
clinical samples – in the case of the assay being developed in this work, the aim was 
to devise an assay for generic evaluation of elevated levels of AVP in human plasma 
samples.  The purpose of validation is to give a method that is reliable and 
repeatable and fit for purpose, where it can quantify the analyte with appropriate 
accuracy and precision [154].  Specific validation criteria are required for each 
analyte to be assessed [60], and are referred to in the FDA guidelines for 
bioanalytical method validations as fundamental parameters [9]; these encompass 
accuracy, precision, selectivity, sensitivity, reproducibility and stability [9].  These 
criteria can be interpreted in many different ways so much so that groups of industry 
analysts have joined forces to develop publications which explain them [60-61].  
The FDA guidelines for bioanalytical method validations [9] and the Crystal City 
guidelines [60-61] among others are major influences on the design of validation and 
the assessments which were made.   
 
Quantification of an analyte for a validation assessment is performed with a series of 
experiments, including quantitation standards, sometimes referred to as calibration 
standards, which are used to generate a calibration line.  The calibration standards 
are samples of the relevant biofluid, for example human plasma, to which have been 
added known concentrations of analyte.  These samples are extracted, after addition 
of an internal standard.  The peak area from the extracted ion (XIC) chromatogram 
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for the analyte is divided by the peak area of the XIC for internal standard, to give 
the peak area ratio.  The peak area ratio is then plotted against the known 
concentration of analyte in the standard.  A line of best fit is then drawn between 
these points on a graph.  The linearity coefficient R
2
 of this line shows how close the 
data points are to the line is also measured to ensure that there are no outliers 
included that may adversely bias the line, which is then used to determine the levels 
of analyte in samples where the concentration is unknown.  To validate a calibration 
curve, sample matrix and analyte spiked frozen standards may be measured against 
it.   
 
1.8.1 Linearity and range 
Linearity is the “extent to which any effect is proportional to its cause” [155].  In 
this case, the area ratio of analyte to internal standard and the nominal concentration 
of analyte are directly proportional.  This proportionality may vary and therefore 
may not be a 1:1 ratio but a curve.  The best and simplest overall linear fit across the 
validation experiments run over the five days in the validation is the one that is 
recommended for sample analysis [61].   
 
1.8.2 Statistical outliers  
For the assessment of statistical outliers, a test must be used to decide if a value is 
anomalous and can therefore be deemed a statistical outlier and excluded from the 
calibration data set.  In deciding this, FDA guidelines must be taken into 
consideration; these stipulate that a minimum of five replicates [9] of the sample 
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matrix AVP spiked frozen plasma standards are required to determine accuracy and 
precision.  If there is one obvious outlier in the data set, a statistical test such as 
Grubbs test [156] can be applied.  This is also the case for two outliers, but if two 
outliers were present then the FDA criteria of a minimum number of five that must 
pass acceptance out of six measured could not be met and subsequently the 
experimental data would not be reported but repeated. 
 
Figure 25- Grubbs test for statistical outliers [20]  
Grubbs = I mean – value to be assessed I 
                       standard deviation 
 
The Grubbs test can only be used when there are six or more data points as it is 
based on a normal Gaussian distribution [157-158]. It works by calculating the 
maximum and minimum values that fall within 95% of the distribution from the 
values of the other five data points and then determines the probability of the sample 
in question being an outlier.   The values are compared to literature values and have 
predefined limits.  If a value falls outside of these limits, then it is excluded.   
 
1.8.3 Accuracy  
The accuracy of a method can be defined as being “the degree of closeness of the 
observed concentration to the nominal or known concentration” [159].  To determine 
the accuracy of an analytical method, the guidelines recommend testing at least five 
replicates of spiked frozen level of analyte for each concentration [159] and at least 
three different concentrations of analyte in plasma [159] in the calibration range.     
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AVP spiked frozen plasma standards are used in this assessment, which can be 
sample matrix aliquots containing known concentrations of the analyte, which have 
been stored in the same way as the anticipated samples.  These should be analysed as 
six replicates and the peak area ratios compared to the line of best fit resulting from 
the calibration standards to ensure that analyte is stable in the sample matrix and that 
the quantitation standards give accurate concentration data.  The overall aim is to 
make sure that the AVP spiked frozen plasma samples give results that are within 
100±15% of the concentrations they are known to be spiked at when compared to 
the calibration line (the line of best fit created from the quantitation standards).  
 
1.8.4 Precision 
When generating scientific data, the precision of replicate measurements is 
important as it refers to the closeness of a set of measurements [160] and can be 
expressed as the coefficient of variation (CV) [160].  The criteria for assessing 
precision are determining whether the values obtained are 100±15% of the known 
spiked concentration [9].  This is tested using the AVP spiked frozen plasma 
standards from which XIC peak area ratios are compared to the calibration curve 
(line of best fit of the calibration points) at the lowest concentration quantified, a 
point three times the lowest, a median value and a point at about 25% from the upper 
limit of detection and the upper limit of quantification..  The purpose of this is to 
show that the results are consistent and reproducible. 
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The coefficient of variation (CV) is also referred to as the relative standard deviation 
(RSD) as it is the standard deviation / mean *100.  This offers a means of 
assessment of the intra-day and inter-day data.  The acceptance criteria are generally 
that no concentration measurement should exceed CV>15% except for at the LLOQ 
which is the lowest limit which can be quantified (with a S:N >5:1)  where CV< 
20% is recommended by the regulatory agencies [159].  
 
1.8.5 Stability   
In the assessment of stability of an analyte, there are important factors for 
consideration in a bioanalytical assay based on the treatment of patient biofluid 
samples and the conditions to which they may be subjected.  The importance of this 
is the integrity of the data produced.  For this purpose, stability standards, prepared 
by spiking the analyte into the biofluid at known concentration and freezing serve 
the purpose, not only to validate the calibration curve but also to prove that the 
initial freezing and defrosting of samples does not impact on the amount of analyte 
quantified in the biofluid.  Once this is determined, it can be furthered by performing 
freezing and storage stability more than once; this is done in a validation as there 
may be the need to re-analyse samples and to do this it is important to know that the 
analyte is stable when this is done.  Analyte stability in biofluids stored at room 
temperature reflects the maximum time samples could be defrosted and then stored 
at room temperature and maintain stability.  The standards are extracted, the peak 
area ratio from the XICs calculated and the concentration taken from the calibration 
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line.  This value is then compared to the known concentration and the accuracy and 
precision calculated.   
 
1.8.6 Matrix effects 
Matrix effects are changes in the amount of analyte detected in the presence of 
matrix.  The matrix is often complex biological material which contains the target 
analyte e.g. plasma, urine.  Its components can interfere with the analyte peak to 
give enhancement or suppression of the analyte signal.  Matrix effects are examined 
during method validation to ensure there is no influence on the reproducibility or 
linearity of the assay as well as the potential sensitivity [161-162].  Matrix effects 
have been observed in fluorescence and electron capture techniques [163-164], 
however they are more commonly associated with LC-MS.  In LC-MS, both 
atmospheric pressure chemical ionisation (APCI) and electrospray ionisation (ESI) 
assays have been shown to be susceptible to matrix effects [165-167].  This is more 
apparent for ESI than APCI [165] and this is thought to be related to their 
mechanism of operation.  The mechanism by which matrix effects influence the MS 
signal is not yet fully understood although suggestions of this being related to 
competition for charges and droplet surface accessibility between target analyte ions 
and matrix components, have been made [165,166-168]. 
 
The FDA requests that steps are taken to limit matrix effects [159] and thus in 
assessing matrix effects, matrix samples from different donors can be used, as 
suggested by Karnes et al [169].  These blank matrix extracts are spiked with analyte 
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and internal standard and the peak area ratios taken from the XIC compared to that 
obtained from a standard solution in the absence of matrix, to determine the amount 
of change to the analyte and internal standard MS signals occurring in the presence 
of matrix.   This approach is consistent with that used by Nadiong et al [170]. 
 
In assessing the impact of matrix effects in a validation, a matrix factor (MF) is 
used.  This is a ratio of the analyte response when matrix is present to the analyte 
response when matrix is absent [61].  The Crystal City II guidelines report that an 
MF of 1 indicates that the matrix does not impact on the analyte response but that an 
MF>1 indicates ionisation enhancement and consequently MF<1 analyte 
suppression [61]. 
 
1.8.7 Selectivity 
The selectivity of an assay is its ability to detect and detect only the target analyte.  
In tandem mass spectrometry, it is not possible to assume that there are no other 
species in the sample that would give both precursor and product ions of the same 
m/z as the analyte, although it is unlikely due to the selective nature of this m/z 
discriminating process in MRM mode. 
 
The selectivity of the MRM transition is in addition to that offered by the sample 
preparation used, such as SPE, which removes interferents, and LC, where the 
analyte needs to be retained by the stationary phase selectively.  It is also important 
to consider the matrix and use a biofluid pool from the appropriate organism, usually 
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human.  Using a number of blank biofluid samples in the assay and screening the 
XIC  for peaks at the retention time of the analyte and internal standard makes it 
possible to determine whether another species at the same retention time as the 
target analyte/internal standard and undergoing the same transition is detectable. 
 
1.8.8 Recovery 
Recovery assessments are made during validation to determine the amount of 
analyte recovered during sample extraction.  The amount of analyte expected to be 
present at the end of the extraction is assessed.    This takes into consideration 
sample volumes used and any transfer steps.  For sample preparation, sample matrix 
with and without analyte may be extracted. A standard solution of analyte in 
injection solvent serves to spike the blank matrix with analyte after the extraction.  
The recovery is calculated by dividing the XIC peak area from the extracted matrix 
spiked with analyte before extraction, by the analyte peak area from the XIC for the 
matrix which is spiked after the extraction.  This value is then multiplied by 100 to 
give a percentage recovery. 
 
1.8.9 Limit of quantification (LOQ) 
The challenges of improving sensitivity in LC-MS/MS assays are well researched.  
Methods range from concentration steps to altering the separation chemistry in SPE 
and liquid chromatography (LC).  The mobile phases used in LC can also impact on 
the sensitivity, especially if a high percentage of organic solvent is present as the 
analyte is ionised, due to more efficient desolvation in the ion source.  
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The limit of quantification is defined as “the lowest concentration of analyte that can 
be quantified and measured with an accuracy and precision of less than 20%” [17].  
Analytical method validation guidelines require the signal to noise ratio of the 
analyte and internal standard XIC peaks must also be greater than or equal to 5:1 
[59].   
 
1.9 Aims  
The research in this thesis is aimed to develop and validate a quantitative 
bioanalytical method for the analysis of arginine-8-vasopressin in human plasma that 
can compete with current detection limits in immunoassays of 1 pg/mL.  This level 
is important because it is the endogenous level of AVP in human plasma.  The levels 
found in disease states as previously mentioned are however much higher.  If a limit 
of detection of 1 pg/mL, was not reached,  an assay with a limit of quantification of 
0.5 ng/mL would be appropriate as a tool to screen for elevated biomarker levels. 
 
In developing a quantitative bioanalytical method with the lowest potential LLOQ 
using the most advanced instrumentation and techniques available to a bioanalytical 
assay I hope to also become trained in the skills which will enable me to develop 
bioanalytical methods.  This will allow me to assess different fractionation, 
separation, mass spectrometric and complementary techniques and will also allow 
analysis and breakdown of the validation requirements of a bioanalytical assay using 
analytical protocols. 
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Chapter 2 -Methods 
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2.0 Methods 
2.1.1 Chemicals   
Acetonitrile, propan-2-ol, phosphoric acid, acetic acid, ammonium acetate and 
ammonium formate, were obtained from ThermoFisher Scientific, UK and were all 
of highest available grade.  Methanol, acetone, and water were HPLC grade 
(Rathburn, UK).  Blank human plasma (EDTA was the anticoagulant at 2 mg/mL) 
was used to prepare the calibration and AVP spiked frozen plasma standards. AVP 
was obtained from Sigma Aldrich, UK and AVP-D5 from Lardon fine chemicals, 
Sweden. All other chemicals and reagents were obtained from VWR international 
limited (Poole, UK).  30 mg HLB and WCX 96 well SPE plates were obtained from 
Waters, Manchester, UK.  Instrumentation included a Waters Acquity system 
(Waters, Manchester, UK) and API 5000 triple quadrupole mass spectrometer 
(Applied Biosystems / MDS Sciex, Canada).  Columns used included Waters BEH 
C18 5 cm * 2.1 mm * 1.7 m and Waters Acquity HILIC C18 5 cm * 2.1 mm * 1.7 
m. 
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2.1.2 Peptide Analytes  
The structures and molecular weights of the peptides analysed in this work are given 
in table 1.   
Table 1 – AVP and AVP-D5 
 
Arginine-8-vasopressin (AVP, MW=1084) 
 
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2  
 
Deuterated Arginine-8-vasopressin (AVP-D5 MW=1089) 
 
Cys-Tyr-Phe(D5)-Gln-Asn-Cys-Pro-Arg-Gly-NH2  
 
2.1.3 AVP concentrated and dilute stock solution preparation 
1 mg analyte and internal standard (AVP, AVP-D5), were accurately weighed and 
dissolved in 1 mL methanol:water:TFA 50:50:0.1 v/v/v.  This was split into 200 µL 
sub aliquots in 0.5 mL plastic microfuge tubes and stored at -20
◦
C.  From this a 
dilute stock solution at 2 µg/mL solutions were prepared by adding 20 µL of the 
concentrated stock solution to 9.98 mL methanol:water:TFA 50:50:0.1 v/v/v. This 
was used on the day of preparation and not stored. 
 
2.1.4 Mass spectrometry optimization (infusion) solution preparation 
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10 µL secondary analyte stock solution was added to 9.99 mL 50 mM ammonium 
formate: acetonitrile: formic acid (50:50:0.5 v/v/v).   
 
2.1.5 Plasma preparation 
Human plasma K2EDTA was received from Biochemed (Winchester, VA).  The 
blood was treated with 2 mg/mL anti-coagulant K2EDTA to prevent the blood from 
clotting and was mixed and centrifuged to remove the plasma within 5 minutes of 
sampling.  This was stored at -20
◦
C. 
 
2.1.6 Quantitation standards 
Quantitation standards were prepared in human plasma K2EDTA.  The analyte was 
spiked into the plasma using the dilute stock solution.   The standards were prepared 
daily in plasma. 
 
2.17 Stability assessment samples 
Stability assessment standards were prepared using human plasma K2EDTA.  The 
analyte was spiked into the plasma using the dilute stock solution.  After spiking, 
these samples were frozen at -20
◦
C.  This differentiated them from calibration 
standards.  They are referred to throughout as AVP spiked frozen plasma standards. 
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2.2 Method development -fractionation techniques 
Quantitation standards were used to assess the suitability of fractionation techniques 
which were designed to optimize the purity of the final sample extract.  Two designs 
were employed, which were reversed-phase and mixed-mode weak cation exchange. 
 
2.2.1 Reversed Phase 
An SPE plate (HLB 30 mg) was primed with 0.5 mL methanol then conditioned 
with 0.5 mL water. 0.5 mL human plasma spiked with 2 g/mL AVP was diluted 
with 0.5 mL 10:90 acetonitrile: water containing 2 g/mL AVP-D5 (the internal 
standard), mixed, and then loaded onto the plate unless otherwise stated.   
 
SPE Profile 1- formic acid  
Elution was performed using 500 µL 2% formic acid and varying the percentage 
methanol in the solution from 5-100 %l.  The extracts were analysed on LC-MS/MS 
as detailed in the final method (section 2.6) and the peak area ratio for AVP: AVP-
D5 determined.   
 
2.2.2 Mixed-mode weak cation exchange 
An SPE plate (WCX 30 mg) was primed with 0.5 mL methanol then conditioned 
with 0.5 mL water. 0.5 mL human plasma spiked with 2 g/mL AVP was diluted 
with 0.5 mL 10:90 acetonitrile: water containing 2 g/mL AVP-D5 (the internal 
standard), mixed, and then loaded onto the plate unless otherwise stated.   
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SPE Profile 2- ammonium hydroxide  
Elution was performed using 500 µL 5% concentrated ammonium hydroxide 
solution and varying the percentage methanol in the solution from 5-100%.  The 
extracts were analysed on LC-MS/MS and the peak area for AVP determined 
 
2.2.3 Validation method 
An SPE plate (WCX 30 mg) was primed with 0.5 mL methanol then conditioned 
with 0.5 mL water. 0.5 mL human plasma spiked with 2 g/mL AVP was diluted 
with 0.5 mL 10:90 acetonitrile: water containing 2 g/mL AVP-D5 (the internal 
standard), mixed, and then loaded onto the plate. The plate was then washed with 0.5 
mL H2O: MeOH (95:5 v/v) to remove aqueous soluble impurities whilst retaining 
the analyte then 0.5 mL H2O: MeOH: NH4OH (20:80:5 v/v/v) and then a third wash 
of 0.5 mL acetone was then used to remove lipid impurities in the plasma whilst 
retaining the analyte.  Two separate elutions of 0.5 mL 
H2O:MeCN:acetone:HCOOH (20:30:50:0.5 v/v/v/v) were performed and collected 
together . 
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2.3 UHPLC   
UHPLC separation techniques were employed in both reversed phase and HILIC 
mode.  Standards were prepared by spiking analyte directly into the solvent 
representative of the gradient starting conditions for each of these analyses.   
 
2.3.1 Standard solution preparation 
A stock solution was used to make standard solutions (in the absence of matrix).  
The spiking scheme and concentrations are given in Table 2.  It was performed in a 
dilution series of your concentrated stock, diluted 1 in 1000 in a volume of 10 mL. 
 
Table 2 –AVP spiking scheme 
Concentration 
of standard 
(pg/mL) 
Concentration of stock used for 
preparation and amount (µL) 
Volume solvent 
(mL) 
Final volume 
(mL) 
1000000000 This is the concentrated stock solution 
10000000   100 µL concentrated stock 
solution 
9.90 10 
100000  1000 µL of 10000000 ng/mL 9.00 10 
10000 1000 µL of 100000 ng/mL 9.00 10 
1000 1000 µL of 10000 ng/mL 9.00 10 
100 1000 µL of 1000 ng/mL 9.00 10 
10 1000 µL of 100  ng/mL 9.00 10 
1 1000 µL of 10 ng/mL 9.00 10 
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2.3.2 Reversed-Phase Chromatography 
An Acquity UHPLC system with integrated auto sampler and column oven was 
used. The column was an Acquity C18 peptide column of length 10 cm, internal 
diameter 2.1 mm, particle size 1.7 µm with a pore size of 130 Å.   
 
The mobile phases used consisted of 0.1% formic acid in water and 0.1% formic 
acid in acetonitrile.  Gradient elution was performed with starting conditions 10% 
mobile phase B for 0.5 min; this was then ramped to 25% B over 1.2 min and held 
there for 0.8 min.  The column was then flushed by ramping to 95% B over 0.5 min 
and holding for 0.5 min.  After 0.1 min it was returned to starting conditions and 
held for 0.4 min.   
 
2.3.3 HILIC Chromatography 
An Acquity UHPLC system with integrated auto sampler and column oven was used 
fitted with an Acquity BEH HILIC column of length 10 cm, internal diameter 2.1 
mm, particle size 1.7 um.  The mobile phases used were phase A = 10 mM 
ammonium formate with 0.5% (v:v) formic acid and B = MeCN .  Gradient elution 
was performed with starting conditions 80% B for 0.25 minutes; ramping to 65% B 
over 2.75 minutes.  Holding for 0.5 minutes.  The column was then flushed by 
ramping to 50% A over 0.5 minutes and holding for 1.0 minutes.  After 0.1 minute it 
was returned to starting conditions and held there for 0.4 minutes.   
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2.4 Method Development - Optimization of Mass Spectrometry Parameters 
 
2.4.1 Fragmentation of Peptides by CID 
Peptides were manually infused at 10 μL/min using the integral syringe driver. 
Detection was performed using an API 5000 triple quadrupole mass spectrometer 
(Applied Biosystems/MDS Sciex (Foster City, CA)).  The ions monitored were m/z 
543.46; m/z 545.5, m/z for the [M+2H]
2+
 ions for each of the peptide analyte and the 
internal standard.  The TurboIonSpray
© 
source temperature was 650 ˚C, with gas 
settings of 50 psi (G1) and 70 psi (G2).  The curtain gas was set to 20 psi and the 
collision gas setting was cad=5.   
 
2.4.2 Collision Energy Setting Optimisation 
[M+2H]
2+
was selected in Q1 and fragmented at a range of collision energy settings 
to give product ion spectra for each analyte.  Q3 scanned m/z 200-1000 to record the 
product ion spectra.  
 
2.4.3 Quantitative Analysis – Limit of Detection Assessment 
Detection was performed using API 5000 and 3000 triple quadrupole mass 
spectrometers (Applied Biosystems/MDS Sciex (Foster City, CA)).  The 
TurboIonSpray
© source temperature was 650 ˚C, with gas settings of 50 psi (G1) and 
70 psi (G2).  The curtain gas was set to 20 psi and the collision gas setting was 
CAD=5.  The transitions monitored for AVP were m/z 543.46 to 328.2.  The dwell 
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time used for each transition was 100 ms with a pause time of 5 ms.  Standard 
solutions of AVP covering the concentration range 0.1 ng/mL to 1 mg/mL were 
analysed using both RP and HILIC columns using 5 µL full loop injections.   
 
2.5 Method development - FAIMS 
 
2.5.1 Sample preparation 
Sample preparation for the assessment of the FAIMS interface comprised analyte 
isolation and concentration using Water‟s Oasis weak cation exchange (WCX) SPE 
(2.2.3). 
 
2.5.2 LC conditions  
LC was performed using an Accela
© 
(ThermoFisher Scientific, Hemel Hempstead, 
UK) UHPLC system, using reversed-phase chromatography on a Water‟s Aquity 
BEH 130 Å  C18 1.7 um, 2.1 x 100 mm column, and  gradient elution as detailed in 
figure 4.   The mobile phases consisted of 0.1% formic acid in water (mobile phase 
A) and 0.1% formic acid in acetonitrile (mobile phase B).  The gradient profile can 
be seen in figure 26 
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Figure 26 - The percentage of mobile phase B (acetonitrile + 0.1% formic acid) 
used over time for gradient elution of AVP in FAIMS experiments 
 
 
 
 
 
 
 
 
2.5.3 FAIMS-MS/MS 
Instrumentation consisted of an Accela
© 
(ThermoFisher Scientific, Hemel 
Hempstead, UK) UHPLC system, interfaced with the FAIMS device and a TSQ 
Ultra triple quadrupole mass spectrometer (figure 27).  Instrumentation conditions 
are given in tables 3-5. 
Figure 27 - FAIMS device with TSQ Ultra QQQ 
 
 
 
 
FAIMS 
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The samples analysed on the instrument included calibration standards containing 
known amounts of AVP spiked freshly into plasma, plasma spiked with known 
amounts of AVP, then frozen and thawed for analysis, and unspiked plasma samples 
where no detectable AVP was present.  The calibration standards were prepared at 
concentrations of 1, 3.125, 20, 47 and 160 ng/mL.  They were extracted as described 
in section 2.6.4.  The samples were injected in duplicate using 20 L injections with 
a 50 L loop, once with, and once bypassing the FAIMS device, to allow direct 
comparisons to be made.  
 
Table 3 -MS conditions 
Parameter Value 
Ion source and polarity  ESI, positive ion mode 
Spray Voltage  3500 V 
Vapouriser Temperature 350 
◦ 
C 
Sheath gas 40 units 
Auxillary gas 60 units 
Tube lens offset 100 V 
Ion sweep gas pressure  60 psi 
Helium: nitrogen 50:50 
Q1 Resolution (where 0.7 is unit resolution) 0.7 
Q3 Resolution (where 0.7 is unit resolution) 0.2 
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Table 4 –m/z values of ions monitored 
Analyte  Q1 Q3 
AVP 543.4 328.2 
AVP-D5  545.5 328.2 
 
Table 5- FAIMS conditions 
Parameter Value 
Dispersion Voltage -5000 V 
Outer Bias Voltage 35 V 
Compensation Voltage -27 V 
Tinner Electrode 70°C 
Touter Electrode 90°C 
Total gas flow 4 mL/min 
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2.6 Quantitation Method for AVP in Human Plasma  
2.6.1 Equipment 
Oasis WCX 30 mg SPE extraction cartridges, UHPLC system, auto sampler, and 
columns (Acquity HILIC, 50 x 2.1 mm i.d, 1.7 µm particle size) were supplied by 
Waters (Manchester, UK), and the API 5000 triple quadrupole mass spectrometer by 
Applied Biosystems (Foster City, CA). 
 
2.6.2 Preparation of Concentrated and dilute analyte stock solutions  
Solutions of AVP and AVP-D5 were prepared in water: acetonitrile 70:30 v/v at a 
concentration of 1 mg/mL and stored at -20˚C.  A diluted solution of the AVP-D5 
internal standard was prepared at 5 ng/mL in acetonitrile:water:trifluoroacetic acid 
10:90:0.1(v/v/v) and was used as the internal standard in the extraction. 
 
 
2.6.3 Preparation of AVP spiked plasma standards  
Quantitation standards were prepared fresh on the day of analysis -the highest 
concentration was prepared using the 1 mg/mL stock solution and this solution of 
AVP spiked into plasma was then serially diluted to generate the calibration 
standards.  Quantitation standard levels were 10, 8, 6, 4, 2, 1, 0.5 and 0.25 ng/mL. 
 
AVP spiked frozen plasma standards were prepared as per section  2.1.8 for the 
calibration standards and then frozen at -20ºC prior to analysis.  AVP spiked frozen 
Page |  
 
79 
plasma standards were prepared at 50 ng/ mL so that a dilution factor could be 
validated ensuring patient samples could be diluted accurately and back calculated to 
the true concentration (if the original concentration was above the highest 
quantitation standard concentration to avoid extrapolation of the calibration curve).  
The concentrations of these standards included the upper limit of quantification 
(ULOQ) at 10 ng/mL, 7.5 ng/mL, 5 ng/mL, 0.75 ng/mL, 0.5 ng/mL and the lower 
limit of quantification at 0.25 ng/mL. 
 
2.6.4 Fractionation techniques for the quantitative analysis of AVP 
0.5 mL plasma (AVP spiked plasma standards or study samples), 0.5 mL internal 
standard solution (AVP-D5 5 ng/mL in methanol) and 100 μL 10% phosphoric acid 
(aq) (used to eliminate protein binding to plasma proteins) were sequentially 
aliquotted into a 96 well plate [mixed and extracted using a Waters Oasis WCX 30 
mg SPE 96-well plate.  A wash step was performed using 0.5 mL H2O: MeOH 
(90:10 v/v), a second wash was performed with 0.5 mL H2O: MeOH: NH4OH 
(80:20:2 v/v/v).  A third wash of 0.5 mL acetone was then used.  Two elutions each 
of 0.5 mL H2O: MeCN:acetone: HCOOH (20:30:50:5 v/v/v/v) were performed 
which were collected into the same vessel to optimise recovery.  The samples were 
then evaporated to dryness in a stream of nitrogen at 40˚C and reconstituted in 100 
µL 20:80:0.5 (v/v/v) water: acetonitrile: formic acid, mixed, sonicated for 5 min at 
ambient temperature and centrifuged (5 minutes, 4ºC, 3000 rpm) prior to LC-
MS/MS analysis. 
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2.6.5 UHPLC-MS/MS for the quantitative analysis of AVP  
UHPLC-MS/MS analysis was performed using a Waters (Manchester, UK) Acquity 
UHPLC system with integrated auto sampler and column oven, and used an Acquity 
BEH HILIC, 1.7 µm, 100 mm x 2.1 mm (i.d) column.  The mobile phases used were 
phase A = 10 mM ammonium formate with 0.5% (v:v) formic acid and B = 
acetonitrile (MeCN).  The gradient consisted of 80% MeCN  for 0.25 min, ramping 
from 80-65% MeCN over 2.75 min, lowering to 50% MeCN over 0.5 min and then 
holding at 50% MeCN for one min before returning to starting conditions over 0.5 
min.  A switching valve was used and diverted to waste between 0-2 min and 3.5-5 
min.   
 
Detection was performed using an API 5000 triple quadrupole mass spectrometer 
(Applied Biosystems/MDS Sciex (Foster City, CA)).   The TurboIonSpray source 
temperature was 650 ˚C, with gas settings of 50 psi (G1) and 70 psi (G2).  The 
curtain gas was set to 20 psi and the collision gas setting was CAD=5.  The 
transitions monitored for AVP were m/z 543.4 to 328.2.  The transitions monitored 
for the internal standard were m/z 545.50 to 328.2.  The dwell time used for each 
transition was 100 ms with a pause time of 5 ms.   
 
The data were processed using the Analyst software (Applied Biosystems, Canada) 
version 1.4.2, to generate peak area ratios from the extracted ion chromatograms 
(XIC) for AVP and AVP-D5 transitions. 
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2.7 Validation of the quantitation method for AVP 
 
2.7.1 Linearity  
The concentration range assessed in this assay was 0.25 ng/mL to 10 ng/mL AVP in 
human plasma, with a sample aliquot volume of 0.5 mL.  The calibration line 
consisted of ten quantitation standards prepared in human plasma, and the peak areas 
for AVP and AVP-D5 were determined from the extracted ion chromatograms.  The 
AVP: internal standard peak area ratio was calculated by dividing the peak area of 
AVP by the peak area of AVP-D5.  The peak area ratio values obtained were plotted 
against concentration of AVP, to generate a calibration line of best fit.   
 
2.7.2 Linear range of the quantitative assay 
The concentration range used in this assay was 0.25 – 10 ng/mL AVP with a dilute 
AVP spiked frozen plasma assessment which was prepared at 50 ng/mL as described 
in section 2.6.3 and frozen at -20 ◦C.  Prior to analysis the 50 ng/mL AVP spiked 
frozen plasma standard was diluted 1:10 with human plasma to give an expected 
AVP concentration of 5 ng/mL.  This was to replicate the dilution of patient samples 
which were above the upper quantification limit of the calibration curve to be 
analysed when diluted with human plasma.   
 
An assessment of the linearity of the line of best fit for the quantitation standards 
was made for each experiment (on each day).  There were five experiments each 
performed on different days  The assessment reflected the a choice of a line of best 
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fit which had a regression curve which matched the calibration and quality control 
standards appropriately. The calibration lines were assessed using different statistical 
weightings to ensure there was less bias on the quantitation points at the top of the 
calibration line.  The simplest regression for the calibration line was used as per 
FDA recommendations [9]. 
 
2.7.3 Matrix effects  
The extraction procedure outlined in section 2.6.4 was performed using AVP or 
AVP-D5 spiked separately into either blank human plasma or HPLC grade water.  
At the end of the extraction, standard solutions of AVP and AVP-D5 were prepared 
separately in water: acetonitrile: formic acid (20:80:0.5 v:v:v).  They were then 
spiked at 5 ng/mL individually into the extracted water and matrix samples, mixed, 
centrifuged and analysed by LC-MS/MS.  The extent to which the matrix affects the 
response of the analyte and internal standard was then calculated by dividing the 
peak area of AVP as taken from the XIC for the MRM analysis of 543.4 to 328.2. 
sections in the presence of matrix by the peak area of AVP in the absence of matrix. 
 
2.7.4 Selectivity 
The selectivity of the quantitation method was assessed by using samples of 
unspiked human plasma from six different people [17-18] as well as a pool of 
plasma from ten individuals, and the impact of interferences on the chromatograms 
assessed visually at the retention times of AVP and AVP-D5.  HILIC 
chromatography was chosen as it would retain analyte and internal standard most 
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effectively was chosen as this would ensure less interferences eluted with the 
analytes due to its polar nature. 
  
2.7.5 Statistical outliers 
The test used in this assessment was the Grubb‟s test G‟ [36] which was used to 
assess if a single outlier was present in the data set.  The exclusion of a data value is 
then based on the fact that with 95% confidence, the value assessed does or does not 
fit within the normal Gaussian distribution of the other five values in the data set.  
 
Accuracy and precision data were generated from the six replicates of each AVP 
spiked plasma standard level in each experiment and calculating the mean and 
standard deviation.  The results were initially assessed by eye and any results that 
appeared to be anomalous were then assessed statistically.   
 
2.7.6 Stability 
The stability of AVP, frozen for 12 hours in plasma and then thawed and analysed 
was investigated using the AVP spiked frozen plasma standards prepared as 
described in section 2.6.3.   Six replicates of these samples at the levels 0.25 ng/mL, 
0.5 ng/mL, 0.75 ng/mL, 3 ng/mL, 5 ng/mL, 7.5 ng/mL and 10 ng/mL were extracted 
and analysed and their XIC peak area ratios for AVP: AVP-D5  Were determined 
and compared to the calibration curve.   
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Six replicates of AVP spiked frozen plasma standards as described in the paragraph 
above, at the levels of 0.75 and 10 ng/mL were used to assess the analytes stability 
in human plasma at room temperature.  These samples consisted of AVP-spiked 
plasma which were frozen at -20˚C for 24 hours [17].  They were then removed from 
the freezer and left at room temperature for 24 hours before being extracted as in 
section  2.6.4.  Recommendations are to store samples at room temperature for 4-24 
hours [17-18] and since this bioanalytical assay required samples to be defrosted for 
more than 4 hours, it was appropriate to assess stability at 24 hours.   
 
Six replicates of AVP spiked frozen plasma standards at the levels 0.75 and 10 
ng/mL were also used to assess the analyte stability in human plasma on being 
frozen and defrosted.  These standards were frozen for 24 hours after preparation, 
defrosted at room temperature for 1 hour and then returned to the freezer.  This 
constituted one freeze-thaw cycle.  Four of these cycles were completed and the 
standards thawed one final time and then assessed. 
 
2.7.7 Maximum AVP recovery in a quanititative method 
The assessment of how much AVP was recovered on extraction carried out as 
described in section 2.6.4 was performed using plasma spiked with AVP at 
concentrations of 0.75 ng/mL, 5 and 10 ng/mL.  The maximum amount (100%) of 
AVP and AVP-D5 which could be recovered when using the fractionation 
techniques from the method detailed in section 2.6.4.  Solutions of AVP in 
water:acetonitrile:formic acid (20:80:0.5 v:v:v) were prepared at the levels as if 
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100% of the analyte was recovered for the extracted analyte concentrations of 0.75 
ng/mL, 5 ng/mL and 10 ng/mL.  The calculation for 5 ng/mL is given in figure 27.      
Matrix blanks from pooled human plasma (ten individuals) was also extracted.  The 
maximum recovery solutions as detailed above were added in place of reconstitution 
solution water:acetonitrile:formic acid (20:80:0.5 v:v:v) to the evaporated matrix 
blank extracts.  These were then mixed, centrifuged and analysed by LC-MS/MS.  
The peak area of the XIC for AVP spiked frozen plasma standards was compared to 
the peak area of the extracted plasma blank which had a solution of AVP in it (at the 
100% recovery concentration) which was spiked with AVP post extraction.  
 
Figure 27- maximum recovery calculation (5 ng/mL AVP in human plasma) 
 
 
 
 
 
 
 
 
 
 
 
  
5 ng in 1000 µL for a 5 ng/mL 
solution gives 2.5 ng/mL in 500 uL 
Add 600 µL Internal Standard /acid 
to give 2.5 ng in 1100 µL 
Sample transferred to SPE cartridge, 
eluted and taken to dryness 
Reconstitute in 200 µL 
2.5 ng in 200 µL 
= 12.5 ng/mL 
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3.0 Results and Discussion 
 
Experimental design in bioanalysis permits many stages in the process.  The first 
stage is method development of a quantitative bioanalytical assay and the second, 
the validation of the quantitative bioanalytical assay.   
 
3.1 Method Development -Results and Discussion 
 
Method development allows decisions to be made based on scientific experiments 
and the understanding of the chemistry behind them.  The aims in all scientific 
investigation, including this method development are not to get the desired result 
every time, but to discover new ways to reach a goal.  In this investigation, the aims 
were to identify suitable approaches to extract AVP from human plasma and 
quantify it by LC-MS/MS.  There were many different approaches which could be 
taken and the testing of them can be referred to as method development. 
 
In this thesis a range of different fractionation techniques, separation techniques and 
mass spectrometric optimisations were assessed, optimised and evaluated.  The 
conclusions drawn from each of them were combined, to arrive at a quantitative 
method for the analysis of AVP in human plasma. 
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3.1.1 Fractionation techniques 
 
The purpose of these experiments was to investigate the optimal conditions for SPE, 
including selection of the cartridges, and the washes and elutions to be used to 
fractionate AVP from the plasma matrix.  The washes needed to elute the minimum 
amount of analyte whilst removing interferences, whereas for the elution solvent, it 
is important to elute as much of the analyte from the SPE cartridge as possible.  To 
achieve this, SPE cartridges were primed and conditioned, and then diluted, 
acidified, AVP-spiked human plasma was loaded onto the extraction cartridge.  HLB 
and WCX were used as they offer both reversed phase and mixed mode ion 
exchange mechanisms both of which are suitable for very basic compounds such as 
AVP (table 1).  
 
0.5 mL Plasma containing 10 ng/mL AVP analyte to be extracted was loaded onto a 
HLB SPE plate (30 mg, Waters, Manchester) in 0.5 mL 0.1% formic acid 
(H2O:MeOH, 90:10 v/v), to prevent AVP from adsorbing to the plastic surfaces.  In 
order to assess the optimal % of methanol for eluting the AVP, a range of % of 
methanol in water (5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100% v:v) acidified with 
0.5 % formic acid were tested in duplicate[figure 28], and the intensity of the AVP 
response assessed using LC-SRM-MS, monitoring the 543.4-328.2 transition.  
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Figure 28- Elution profile for AVP when varying amounts of methanol were 
added to an elution solution containing 0.5% formic acid 
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Figure 28 shows the area of the AVP peak obtained on UHPLC-SRM-MS analysis 
of the eluted AVP when the amount of methanol in the wash acidified with 0.5% 
formic acid is varied.   At 5% methanol, there is very little analyte eluted.  From 5% 
to 60% methanol, it is apparent that there is an increase in the amount of analyte 
eluted as the percentage methanol in the solution is increased.  From 60%-100% 
methanol there is a plateau, with a slight decline in analyte recovery at 100%.   From 
this data, it can be concluded that 5% methanol can be used to remove interferences 
but not analyte, as this solvent may be expected to remove water soluble matrix 
components without very much elution of the AVP analyte.  It can also be 
determined that an appropriate percentage of methanol to elute AVP and to achieve 
maximum recovery would be 90%.  This would also be suitable for rapid 
evaporation and would result in fast analysis times. 
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In order to improve the retention and further remove interferences, an additional 
mechanism can be used in the form of a WCX cartridge.  This contains a carboxylic 
acid group in addition to the divinlbenzene polymer. 0.5 mL plasma containing 10 
ng/mL AVP was loaded onto the SPE plate in 0.5 mL 0.1% formic acid 
(H2O:MeOH, 90:10 v/v) . In order to assess the optimal percentage of methanol for 
eluting the AVP, a range of percentage of methanol in water (5, 10, 20, 30, 40, 50, 
60, 70, 80, 90 and 100% v:v) in a basic solution of 2% ammonium hydroxide tested 
in duplicate [figure 29], and the intensity of the AVP response assessed using LC-
SRM-MS, monitoring the 543.4-328.2 transition.  
 
Figure 29- Elution profile for AVP when varying amounts of methanol were 
added to an elution solution containing ammonium hydroxide 
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 In figure 29, the mass spectrometric AVP response versus percentage methanol in 
the wash solution is plotted.  The data show that elution with between 5% and 30% 
methanol yields little or no analyte response.  This is in contrast to the data shown in 
figure 28, and can be explained by the combined positions where the AVP can 
interact, these positions are on the carboxylic acid and also the benzene ring 
(structure shown figure 4) which are ionized by in the presence of 5% ammonium 
hydroxide.  This retention can be seen by comparing figures 28 and 29.  It is clear 
that from 0-25% Methanol that no elution of AVP occurs in the presence of 
ammonium hydroxide, whereas elution is seen from 5% Methanol in the presence of 
formic acid.  This indicates that the ammonium hydroxide is increasing the 
interaction and retention of AVP to the SPE sorbent. 
 
From 30% to 60% methanol there is a sharp increase in analyte response, which 
decreases again from 70% to 100% methanol.  As the purpose of this experiment 
was to allow the N-vinylpyrrolidione part of the polymeric stationary phase to bind 
with the AVP, retention during the extraction was the aim. 
These two profiles were used in combination to give the method bellow: 
 
The stationary phase was primed with 0.5 mL methanol then conditioned with 0.5 
mL water to equilibrate the stationary phase, followed by loading the sample, which 
contained 0.5 mL plasma containing 10 ng/mL AVP, 0.5 mL H2O:MeOH:TFA 
(90:10:0.1 v/v/v) and 100 μL ortho-phosphoric acid (10% concentrated ortho-
phosphoric acid in water). The methanol was to prevent the analyte adsorption to the 
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sample tube, TFA was used as an ion-pairing agent and ortho-phosphoric acid was 
included to prevent binding of the analyte to protein in plasma.  As there are two 
elution profiles, they can both be used in recovery optimisation and sample 
purification.  This can be done by using figure 28 which shows that 0.2% formic 
acid in 95:5 water:methanol will elute very little compound but will remove many 
water soluable components, this can also be used with the WCX as the sorbent 
structure is the same except for the addition of the carboxylic acid group.  This 
should therefore behave in the same way for WCX as HLB in the presence of acid as 
the carboxylic acid will be protonated.  The second wash, used for the removal of 
both some lipophilic plasma component removal in addition to any more polar 
components was consequently set at 20% methanol .  This is based on the 
characteristics of the reagents and how they interact with polar and non-polar 
compounds.   
 
  The first wash used was H2O: MeOH (90:5 v/v), used to remove water soluble 
plasma components and to keep the plate neutral and charged.  Interactions take 
place between the stationary phase phenyl ring, which interact with AVP by binding 
to the phenyl ring on the phenlalanine, so on loading, the primary interactions were 
reversed phase.  On washing with the 90:5 H2O:MeOH the carboxylic acid group 
was deprotonated and the AVP is expected to bind via both RP and ion exchange 
mechanisms.   
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A third step was trialled and this was a wash with 0.5 mL acetone.  This was to 
ensure lipid removal from the stationary phase prior to analyte elution.  The elution 
solution comprised H2O: MeCN: HCOOH (20:80:5)  with the acid included to elute 
the cationic AVP from the carboxylic acid groups in the ion-exchange resin; 
ultimately the sorbent-reagent interaction is greater than the sorbent-analyte 
interactions and therefore the analyte is eluted. 
 
3.1.2 Separation techniques 
The purpose of this experiment was to determine if there was a difference in the limit 
of detection which could be reached when comparing AVP spiked into solvent 
suitable for injection onto the chromatographic column it was trailed on, using RP 
and HILIC chromatography.  
 
Various concentrations of AVP were analysed by both RP and HILIC UHPLC- 
SRM-MS/MS and the XIC peak area for AVP measured in each case. The results are 
shown in table 6.   
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 Table 6 - Peak Areas of for AVP analysed using RP-UHPLC-SRM-MS/MS and 
HILIC-UHPLC-SRM-MS/MS 
 
 
 
The results in table 6 show that the peak areas for HILIC analysis are greater than 
for those of reversed-phase analysis for the same amounts of AVP.  This is probably 
due to improved ionization efficiencies when eluting the analyte at higher levels of 
organic solvent, which is the case in HILIC chromatography.  The extracted ion 
chromatograms for 1 ng/mL AVP are given in figure 30, which also show a larger 
sharper peak at this level for HILIC analysis when compared to RP.  
 
Concentration 
AVP (ng/mL) 
AVP peak area 
reversed-phase 
(cps) 
Reversed phase 
AVP tR (min) 
AVP peak 
area HILIC 
(cps) 
HILIC 
tR (min) 
1 104 1.97 128 1.67 
10 1202 1.96 1381 1.68 
100 13332 1.96 14121 1.68 
1000 123487 1.95 142329 1.68 
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Figure 30 – Extracted ion chromatograms obtained from injection of 1 ng/mL 
AVP, RP (tR =1.96 min) and HILIC (tR=1.58 min) 
 
 
These results show that HILIC chromatography is more suitable than RP 
chromatography for the analysis of AVP in human plasma and so was used in the 
quantitative method (section 2.2). 
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3.1.3 Internal Standards in quantitative analysis 
AVP is the analyte in this validation and the purpose is to quantify it.  AVP is 
extracted in the presence of a deuterated internal standard AVP-D5, where the 
deuteriums are on the phenylalanine ring.  This is of particular significance to the 
MRM transitions selected.  The internal standard showed co-elution (or very slight 
separation) with the analyte in the majority of trials, due to the deuterium atoms 
being smaller than hydrogen. 
 
 
3.1.4 Optimisation techniques in quantitative mass spectrometry  
 
Precursor and product ion Identification  
In order to record peptide product ion spectra, infusions were carried out using 
solutions of AVP and AVP-D5 (in MeOH:H2O:HCOOH 50:50:0.1 v/v/v) prepared 
at 1 ng/mL and infused at 10 µL/min.  They were ionised using TurboIonSpray and 
their product ion spectra recorded in positive ion mode, where the analyte precursor 
ion was selected in Q1 and then fragmented in the collision cell.  In Q3 all the ions 
in the range m/z 200-1000 were scanned (figure 31); this then gives a detailed 
picture of how the analyte breaks down and this can be rationalized in terms of the 
peptide‟s primary structural.  Figures 33-34 give the product ion spectra of AVP and 
AVP-D5. 
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Figure 31 – product ion scan 
           Q1    collision cell           Q3 
 
 
A proposed mechanism for peptide fragmentation is given in figure 21.  This 
produces b and y ions as shown in figure 32.  
 
Figure 32– peptide sequence ions of the b and y series 
 
Determination of the ion to be monitored in Q1 was decided based on ion intensity 
where [M+ 2H]
2+ 
was the most abundant ion.. The product ion to be selected for 
MRM analysis is also shown in figures 33-34.  A common fragment for these two 
peptides is the y3 ion.  This fragmentation is favorable as the AVP has a disulfide 
link between the two cysine residues in the peptide (table 1) and thus y type 
fragmentation occurs to give the y3 ion.  Subsequently the y3 ions are chosen for 
analysis in Q3 for MRM analysis.
[M+H]
+
 ion 
selected 
[M+H]
+
 ion 
fragmented 
m/z 200-1000 
scanned  
Page |  
 
97 
 
 
 
Figure 33- prominent ions in the product ion spectrum of AVP  
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 Figure 34- prominent ions in the product ion spectrum of AVP-D5  
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3.1.5 Comparison of API 3000 and API 5000 instruments for the quantitation 
of AVP 
In order to determine the limits of detection for AVP using the API3000 and 
API5000 triple quadrupole mass spectrometers, equal-sized aliquots of standard 
solutions of AVP containing 0.5, 5, 50, 500 and 5000 pg/mL AVP were injected 
onto the UHPLC system using the HILIC separation developed (section 2).  The 
API3000 and API5000 instruments are comparable in design, with the API3000 
being an earlier model and the API5000 incorporating more recent design 
developments; the specifications of the API5000 include the advantages of an 
additional RF only quadrupole (Qjet) on the front of the analyser, between Q1 and 
the ionization source.  For increased ion focusing, as well as a redesigned ionization 
source, which maximizes ionisation efficiency and analyte transfer into the mass 
analyzer.  
 
 In order to compare the performance of the two instruments for the detection of 
AVP, the peak obtained for AVP on selected reaction monitoring of the transition 
m/z 543.4-328.20 was plotted for each of the five analyte dilutions (figures 35-39). 
Figure 35, shows the XIC for AVP on both an API 3000 (a) and an API 5000 (b) 
with 0.5 pg AVP on the column.  This clearly shows that no AVP can be detected 
when using an API 3000 instrument whereas analyte is detected when using an API 
5000.  Figure 36 shows the XIC for AVP on both an API 3000 (a) and an API 5000 
(b) with 5 pg AVP on the column.  The chromatograms show that the intensity is 
much greater when detection is performed using an API 5000.  This is also the case 
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for figure 37 where 50 pg AVP was analysed, for figure 38 where 500 pg AVP was 
analysed on column and figure 39 where 5000 pg was analysed on column.  From 
these chromatograms it can also be seen that AVP elutes with a retention time of 
1.80 min (API3000 system) or 1.82-1.83 min (API5000), and an intense and sharp 
peak was observed for AVP in all the chromatograms obtained on the API5000.  For 
the API3000, intense, sharp peaks were obtained at this retention time from the 5, 
50, 500 and 5000 pg injections, but no peak was discernible at this retention time 
from the 0.5 pg injection.
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Figure 35–XIC for 0.5 pg of AVP using A) API 3000 and B) API 5000 
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                                                                      Figure 36 – XIC for 5 pg of AVP using A) API 3000 and B) API 5000 
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Figure 37- XIC for 50 pg of AVP using A) API 3000 and B) API 5000  
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Figure 38- XIC for 500 pg of AVP using A) API 3000 and B) API 5000 
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Figure 39 XIC for 5000 pg of AVP using A) API 3000 and B) API 5000 
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From these results, it is clear that using an API 5000, 0.5 pg on column AVP can be 
detected from standard solution, whereas the lowest amount detectable using an API 
3000 is 5 pg.  The API 5000 is therefore a more suitable instrument for use in the 
quantitative analysis of AVP if amounts less than 5 pg need to be detected.  Applied 
Biosystems, the manufacturer of the two instruments, suggest this is due to 
improvements in the ionisation efficiency of the source on the API5000.   
 
 
3.1.6 FAIMS 
In the assessment of the potential of the FAIMS device for improving the detection 
of AVP in human plasma by lowering background chemical and endogenous noise, 
samples of AVP spiked freshly into human plasma, plasma spiked with AVP then 
frozen and rethawed for analysis, and unspiked plasma samples were extracted using 
weak cation exchange SPE cartridges.  A calibration curve was constructed using the 
peak areas obtained on LC-MRM analysis, both with and without the FAIMS 
device, of the plasma spiked with known amounts of AVP (six replicates were 
analysed for each of the 1, 3.125, 20, 47 and 160 ng/mL levels)).  Six replicates of 
the AVP spiked frozen samples were prepared and analysed using LC-MRM both 
with and without the FAIMS device; the amounts of AVP in these samples were 
determined from the peak areas of the AVP peak using the calibration curve.  The 
accuracy values at the 
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LLQQ were 7.0% from the nominal value and with FAIMS 3.3% from the nominal 
value.  The precision values at the LLOQ were 4.9% without FAIMS and 7.2% with 
FAIMS.  The accuracy and precision values for both sets of data met the precision 
and accuracy criteria for validations laid down by the FDA [9] and industry 
guidelines [60-61] as described in chapter 1. 
 
table 4 shows that there is improved precision when not using FAIMS, which can be 
explained as FAIMS reduces the number of ions reaching the detector; it would 
therefore be expected to have lower precision as there are lower numbers of ions to 
be detected.  There was very little difference in the accuracies when FAIMS was 
utilised or bypassed.  
 
As both the data obtained with and without the FAIMS device met the criteria for 
validation, the limits of detection were then compared.  
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Table 7- LC-MS/MS 
precision and accuracy of AVP in spiked frozen plasma samples  
  concentration AVP spike introduced (ng/mL) 
    1    3.125    20    47    160  
     observed concentration (ng/mL) 
mean (ng/mL) 1.07   3.14   19.5   46.7   161 
standard deviation (n-1) 0.0526   0.141   0.811   1.63   3.83 
precision (%) 4.9   4.5   4.2   3.5   2.4 
accuracy (%) 107.0   100.5   97.5   99.4   100.6 
           
Table 8- LC-FAIMS-MS/MS 
precision and accuracy of AVP in spiked frozen plasma samples  
  concentration AVP spike introduced (ng/mL) 
    1    3.125    20    47    160 
   observed concentration (ng/mL) 
mean (ng/mL) 0.967  3.06  20.0  48.8  165 
standard deviation (n-1) 0.0693  0.181  1.66  2.45  7.50 
precision (%) 7.2  5.9  8.3  5.0  4.5 
accuracy (%) 96.7  97.9  100  103.8  103.1 
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To evaluate whether there are changes in the limits of detection with and without 
FAIMS, the signal-to-noise ratios (S:N) for the extracted ion peak for AVP for 
spiked frozen plasma samples were compared (table 9).  The results show the 
analyte peak height divided by the height of the background noise for different AVP 
concentrations in plasma.  The data in table 9 shows that when using FAIMS, the 
S:N ranges from 4.6-1550 whereas without FAIMS it ranges from 3.2-995.  For 
validation, the overall aim of the work described in this thesis, it is desirable to have 
S:N values in excess of 5:1 [9].  Although neither of the methods meets this criterion 
for AVP at 1 ng/mL, using FAIMS brings improved S:N when analysing AVP at 
this level, and at all other concentrations tested.  However there is not an 
improvement in the limit of detection, as table 9 shows that the 1 ng/mL level  does 
not meet the S:N requirements (5:1) as using FAIMS gives a S:N of (4.6:1) whereas 
without FAIMS (3.2:1).  This criterion has been met under both conditions for the 
concentration 3.125 ng/mL. 
 
Table 9 –S:N for AVP extracted ion chromatograms from spiked frozen plasma 
sample with and without FAIMS 
  
Spiked AVP Concentration in human plasma  
1 
ng/mL 
3.125 
ng/mL 
20 
ng/mL 
47 
ng/mL 
160 
ng/mL 
Mean S:N without FAIMS 3.2 15.8 116 773 995 
Mean S:N with FAIMS 4.6 23.7 229 956 1550 
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As well as lowering baseline noise and subsequently increasing the S:N, FAIMS acts 
to separate and remove co-eluting interferences from the analyte peak.  To determine 
whether differences are observed in the XIC for AVP (m/z 543.4 -328.2) two 
aliquots of 3.25 ng/mL AVP spiked into plasma, one analysed utilising and the other 
bypassing the FAIMS interface (figure 40), were compared.  
 
It can be seen in the top chromatogram that there is a shoulder on the main AVP 
peak at 2.0 minutes.  This is believed to be an interfering peak and is not apparent 
when FAIMS is used (bottom chromatogram).  The S:N is also noticeably improved 
when using FAIMS; the peak for AVP at tR 2.1 min in the top chromatogram gives 
S:N of 13:1, whereas the peak for AVP in the bottom chromatogram gives S:N of 
22:1.  This clearly shows that although a lower detection limit (the lowest 
concentration where the S:N ≥5:1) could not be reached by using FAIMS, the 
analysis is more selective when used in conjunction with FAIMS. 
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Figure 40- XIC for 3.25 ng/mL AVP spiked into plasma, analysed without (upper panel) and with (lower panel) FAIMS 
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3.2 Validation of the quantitative bioanalytical method for AVP 
 
The second stage in development of a bioanalytical method is its validation.   This is 
crucial prior to sample quantitation using the method as it establishes the robustness 
of a method, ensuring that sample analysis will result in precise, accurate results for 
the amount of analyte in the analytical samples.   
 
The purpose of this bioanalytical method validation was to determine whether the 
method developed (section 2.0) would satisfy the requirements of industry 
guidelines as set out by the FDA, MHRA and EMEA.  If the method failed to 
comply with these guidelines, it may be deemed unsuitable and subsequent sample 
analysis not appropriate for regulatory submission for NCEs. 
 
 
In order for concentration determination of AVP in human plasma to be possible, 
there needs to be proof that the method is appropriate for this purpose.  This begins 
with the construction of the calibration line.  A calibration line formed from of the 
line of best fit for the quantitation standards in the range 0.25 ng/mL to 10 ng/mL 
AVP prepared in human plasma.  These standards were extracted in the presence of 
AVP-D5 internal standard as described in section 2.2 and analysed by LC-MS/MS 
using MRM for the transitions 543.4 and 545.5 to 328.2   The peak areas at the 
retention time for AVP and AVP-D5 from the extracted ion chromatograms (XIC) 
were determined and the ratio of AVP: AVP-D5 for the peak areas calculated.  This 
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area ratio was plotted in a graph against the known concentration of AVP in the 
original plasma samples.  The relationship between the peak area ratio and AVP 
concentration is defined by a line of best fit between the quantitation standard points.  
Experiments were performed and the area ratio of the sample compared to those of 
the line. Other standards quantified by the line included AVP spiked, frozen plasma 
samples which were stored for 24 hrs at room temperature;  AVP spiked frozen 
plasma samples which were frozen and defrosted twice prior to analysis. Human 
plasma without AVP, and solutions containing AVP without human plasma were 
also analysed.  The purpose of these analyses was to test if AVP was stable at room 
temperature for 24 hours in plasma, if AVP was stable in plasma that had been 
frozen and defrosted twice, also other experiments were required to assess recovery 
and ensure that there were no endogenous interferences.   
 
3.2.1 Construction of Calibration Curve 
In order to determine the linearity of response, five replicate sets of quantitation 
standards, each set prepared on a different day but using the same plasma and dilute 
stock solution were prepared, each containing 10 different concentration levels of 
0.25, 0.5, 1, 2, 3, 4, 6, 8, 9 and 10 ng/mL in human plasma.  This will be referred to 
as inter and intra-day data, and will show that the assay is robust and reproducible on 
different days. 
 
The aim of the experiment was to assess the lowest level which could be quantified 
by LC-MS/MS.  This was because I wanted to have a calibration range appropriate 
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to assess the levels of AVP in human plasma samples, where elevated levels of AVP 
may act as a biomarker for disease states, a suitable LLOQ for this kind of 
assessment would be below 1 ng/mL (chapter 1).   The lowest levels assessed were 
at 0.1 ng/mL and 0.25 ng/mL.  The level 0.1 ng/mL was also included however the 
XIC for 543.4>328.2 did not give a peak for AVP and subsequently no data could be 
reported.  The next level which was assessed was 0.25 ng/mL and therefore the 
range of the quantitation standards, and ultimately the range for which plasma 
samples of unknown AVP concentrations could be assessed, was therefore 0.25 
ng/mL to 10 ng/mL.   Therefore the range was limited to 0.25 ng/mL to 10 ng/mL. 
 
The quantitation standards were extracted using the method described in section 2.2 
and analysed using HILIC UHPLC-MS/MS using multiple reaction monitoring for 
the ions 543.4>328.2.  The peak area for AVP was determined from the extracted 
ion chromatogram and divided by the peak area of the internal standard obtained in 
the same way.  This was plotted against the nominal concentration of AVP.  The 
simplest appropriate form of regression was chosen as required by the FDA [17]   In 
this case it was linear 1/x where x was the concentration.  This gave the calibration 
curve a stronger weighting towards the lower end of the calibration curve. 
 
3.2.2 Accuracy, precision and statistical analysis 
Prior to the assessment of the accuracy and precision of the AVP spiked frozen 
plasma sample outliers were removed using the Grubbs test.  The single outlier test 
was used and this is based on a normal Gaussian distribution of points, which 
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calculates the probability of the suspected outlier of being part of the normal 
distribution generated by the other five values.   
In order to determine how close a value is to the nominal concentration, it is 
important to know what it is being measured against.  In this validation there were 
five experiments performed, each of which consisted of measuring six replicates of 
different levels of AVP spiked into plasma at the levels 0.75, 5 and 10 ng/mL.  All 
samples were measured using the peak area ratios for the XICs of AVP and AVP-
D5. 
  
Precision was determined by assessing the distribution of AVP values obtained on 
analysing six replicate extracted AVP spiked, frozen plasma samples each at 
concentrations 0.25, 0.5, 0.75, 5, 7.5 and 10 ng/mL AVP spiked into human plasma.  
These values were measured against the calibration line, and compared to the known 
amount of AVP in the AVP spiked frozen plasma standards. 
 
The AVP: AVP-D5 XIC area ratios of the AVP spiked frozen plasma standards are 
compared to the calibration line to determine the concentration of AVP in unknown 
plasma samples.  It is therefore important that the line be a true reflection of AVP 
concentrations at the levels spiked into plasma.  The AVP spiked plasma samples 
confirm whether or not the samples are stable when frozen.  
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The quantitation standard data are reported in table 11 and this shows all values to 
be consistent with guidelines including the FDA and MHRA for bioanalytical 
methods [18].   
 
Table 11 shows the data collected from the AVP spiked plasma quantitation 
standards at the levels 0.25, 0.5, 1, 2, 3, 4, 6, 8, 9, 10 ng/mL from the five different 
days; this is referred to as inter-day data and gives the accuracy and precision values 
comparing the standards on different days.  The results show that the accuracy was 
within ±4.8% of the nominal spiked concentration and the precision (given as 
relative standard deviation) below 8.6%.  The requirements for this validation were 
to meet the FDA guidelines, was to be within ±15% of the nominal spiked 
concentration.  These results are within that criterion. 
 
Accuracy and precision was also assessed for the spiked, frozen plasma samples 
which were analysed using six replicate AVP spiked samples at each level on the 
same day.  This was performed on five days and the results collated and compared to 
show that the assay was repeatable.   
 
The results in table 12 show the accuracy and precision data for the spiked frozen 
stability samples for the levels 0.25, 0.5, 0.75, 5 and 10 ng/mL which were extracted 
and analysed on day 1.  The requirement for the data was for the mean concentration 
to be within ±15% of the nominal concentration and also within ±15% for precision.  
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The data shown in table 12 meets these requirements as the accuracy is within ± 13.6 
% of nominal spiked concentration and the precision within 9.2 %.    
 
 The results in table 13 show the accuracy and precision data for the spiked frozen 
stability samples for the levels 0.25, 0.5, 0.75, 5 and 10 ng/mL which were extracted 
and analysed on day 2.  The requirement for the data was for the mean concentration 
to be within ±15% of the nominal concentration and also within ±15% for precision.  
The data shown in table 13 meets these requirements as the accuracy is within ± 13.2 
% of nominal spiked concentration and the precision within 8.1 %.     
 
The results in table 14 show the accuracy and precision data for the spiked frozen 
stability samples for the levels 0.25, 0.5, 0.75, 5, 10 and 50 ng/mL which were 
extracted and analysed on day 3.  The requirement for the data was for the mean 
concentration to be within ±15% of the nominal concentration and also within ±15% 
for precision.  The data shown in table 14 meets these requirements as the accuracy 
is within ± 6.6 % of nominal spiked concentration and the precision within 13.7 %.   
 
The results in table 15 show the accuracy and precision data for the spiked frozen 
stability samples for the levels 0.25, 0.5, 0.75, 5 and 10 ng/mL which were extracted 
and analysed on day 4.  The requirement for the data was for the mean concentration 
to be within ±15% of the nominal concentration and also within ±15% for precision.  
The data shown in table 15 meets these requirements as the accuracy is within ± 5.8 
% of nominal spiked concentration and the precision within 10.6 %.  
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The results in table 16 show the accuracy and precision data for the spiked frozen 
stability samples for the levels 0.25, 0.5, 0.75, 5 and 10 ng/mL which were extracted 
and analysed on day 5.  The requirement for the data was for the mean concentration 
to be within ±15% of the nominal concentration and also within ±15% for precision.  
The data shown in table 16 meets these requirements as the accuracy is within ± 13.6 
% of nominal spiked concentration and the precision within 8.8 %.  
 
Data were also collated from the experiments performed on different days.  This is 
referred to as the inter-day results as is given in table 17.  The accuracy and 
precision of AVP spiked frozen plasma standard (AVP spiked frozen plasma 
standards) AVP concentrations to the mean was compared for experiments 
performed on different days to ensure repeatability.  These experiments all used 
different batches of SPE cartridge for sample preparation and mass spectrometers for 
quantification and detection.  This was to ensure the experiments were robust and 
repeatable. 
 
The results in table 17 show the mean accuracy and precision data for the spiked 
frozen stability samples for the levels 0.25, 0.5, 0.75, 5 and 10 ng/mL assessed over 
five days, where the data from tables 12-16 has been collated.  The requirement for 
the data was for the mean concentration to be within ±15% of the nominal 
concentration and also within ±15% for precision.  The data shown in table 17 meets 
these requirements as the accuracy is within ± 7.6 % of nominal spiked 
concentration and the precision within 11.1%.  
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All intra-day and inter-day statistics in tables 12- 17 shows that the acceptance 
criteria as defined by the regulatory agencies has been met [15-18].    
 120 
 
 
 
 
 
 
 
 
Table 11 
inter-day precision and accuracy of  quantitation standard data 
  quantitation standard level (ng/mL) 
    0.25 0.5 1 2 3 4 6 8 9 10 
mean (ng/mL) 0.238 0.504 1.04 2.07 2.99 4.09 6.04 7.83 8.79 10.1 
standard deviation (n-1) 0.0204 0.0271 0.0425 0.0480 0.127 0.136 0.227 0.358 0.277 0.284 
RSD (%)   8.6 5.4 4.1 2.3 4.2 3.3 3.8 4.6 3.2 2.8 
accuracy (%) 95.2 100.8 104.0 103.5 99.7 102.3 100.7 97.9 97.7 101.0 
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Table 12 
intra-day precision and accuracy data of AVP spiked frozen plasma samples  
experiment 1 – day 1 
AVP 
concentration 
    0.25 ng/mL   0.5 ng/mL   0.75 ng/mL   5 ng/mL   7.5 ng/mL 
     observed concentration (ng/mL) 
mean (ng/mL)   0.284   0.526   0.791   4.99   7.24 
standard deviation (n-1) 
  
0.0261   0.0391   0.0630   0.171   0.213 
RSD (%)     9.2   7.4   8.0   3.4   2.9 
accuracy (%)   113.6   105.2   105.5   99.8   96.5 
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Table 13 
intra-day precision and accuracy data of AVP spiked frozen plasma samples  
experiment 2 – day 2 
 AVP concentration   0.25 ng/mL   0.5 ng/mL   0.75 ng/mL   5 ng/mL   10 ng/mL 
     observed concentration (ng/mL) 
mean (ng/mL)   0.283   0.521   0.818   4.82   9.82 
standard deviation 
(n-1) 
  0.0228   0.0403   0.0409   0.246   0.536 
RSD (%)     8.1   7.7   5.0   5.1   5.5 
accuracy (%)   113.2   104.2   109.1   96.4   98.2 
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Table 14 
intra-day precision and accuracy data of AVP spiked frozen plasma samples  
experiment 3 –day 3 
 AVP 
concentration 
0.25 ng/mL   0.5 ng/mL   0.75 ng/mL   5 ng/mL   10 ng/mL   50 ng/mL* 
     observed concentration (ng/mL) 
mean (ng/mL) 0.237   0.480   0.739   4.67   9.49   50.5 
standard 
deviation (n-1) 
0.0325   0.0131   0.0407   0.199   0.229   2.16 
RSD (%)   13.7   2.7   5.5   4.3   2.4   4.3 
accuracy (%) 94.8   96.0   98.5   93.4   94.9   101.0 
* analysed after ten-fold dilution with blank human plasma to validate samples above range being diluted into range 
with blank plasma. 
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Table 15 
intra-day precision and accuracy data of AVP spiked frozen plasma samples  
experiment 4 – day 4 
 AVP concentration 0.25 ng/mL   0.5 ng/mL   0.75 ng/mL   5 ng/mL   10 ng/mL 
     observed concentration (ng/mL) 
mean (ng/mL) 0.257   0.500   0.713   4.71   9.47 
standard deviation 
(n-1) 
0.0215   0.0429   0.0753   0.134   0.349 
RSD (%)   8.4   8.6   10.6   2.8   3.7 
accuracy (%) 102.8   100.0   95.1   94.2   94.7 
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Table 16 
intra-day precision and accuracy data of AVP spiked frozen plasma samples  
experiment 5 –day 5 
  AVP concentration   0.25 ng/mL   0.5 ng/mL   0.75 ng/mL   5 ng/mL   
     observed concentration (ng/mL)   
mean (ng/mL)   0.284   0.527   0.797   4.92   
standard deviation (n-1)   0.0127   0.0466   0.0446   0.0818   
RSD  (%)     4.5   8.8   5.6   1.7   
accuracy (%)   113.6   105.4   106.3   98.4   
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Table 17 
inter-day precision and accuracy data of AVP spiked frozen plasma samples  
    0.25 ng/mL 0.5 ng/mL 0.75 ng/mL 5 ng/mL 7.5 ng/mL 10 ng/mL 50 ng/mL 
   observed concentration (ng/mL) 
mean (ng/mL) 0.269 0.512 0.770 4.82 7.24 9.59 50.5 
standard 
deviation (n-1) 
0.0299 0.0403 0.0646 0.204 0.213 0.403 2.16 
RSD  (%)   11.1 7.9 8.4 4.2 2.9 4.2 4.3 
accuracy (%) 107.6 102.4 102.7 96.4 96.5 95.9 101.0 
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3.2.3 Stability 
In the assessment of stability, three experiments were performed.  The first assessed 
the short term stability of AVP in plasma over five days when stored at -20
◦
C.  Other 
experiments assessed the room temperature stability and freezing / defrost stability 
of AVP in human plasma.  The aim of these experiments was to show whether or not 
AVP was stable in human plasma at -20◦C for up to five days, if it could be stored at 
room temperature for 24 hours and still be stable and also if it could be frozen and 
defrosted up to four times.   
 
Spiked frozen plasma samples at AVP concentrations 0.75 ng/mL and 10 ng/mL 
were used to assess the frozen stability of AVP in human plasma, the room 
temperature stability of AVP in plasma and the freezing and thawing stability of 
AVP in human plasma.  They were prepared as per section 2.2.  These were then 
analysed using six replicate samples at each concentration, and the concentration of 
AVP determined by comparison to the calibration curve .  The data in tables 12-17 
show that the accuracy and precision meet the acceptance criteria initially set out in 
the introduction and taken from the FDA and MHRA guidelines [17].  It can be 
concluded that AVP is stable in plasma according to these guidelines [17] over 5 
days (which was the longest amount of time the AVP spiked frozen plasma samples  
were stored for and then compared to unfrozen quantitation standards.   
 
The stability of AVP in human plasma was trialed for 24 hrs at room temperature by 
preparing spiked, frozen plasma samples and freezing these for 24 hours, then 
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storing at room temperature for 24 hours before analysis.  AVP spiked plasma 
samples were also used in the assessment of freeze-thaw stability.  This involved 
freezing the standards for 24 hours then defrosting them for 1 hour at room 
temperature; the samples were then returned to the freezer for 12 hours then 
defrosted for 1 hour at room temperature.  This process was repeated until the 
standards had been frozen and defrosted in total four times.  This was to test whether 
patient samples could be frozen and defrosted in this way without affecting the 
quantity of AVP detected. 
 
The data in table 18 shows the concentrations of AVP spiked into human plasma 
compared to the concentrations of AVP determined experimentally in the samples 
frozen for 24 hours then extracted.  The data in table 18 shows that  there is good 
accuracy and precision at both the 0.75 and the 10 ng/mL levels, which is indicated 
by the accuracy being within 8% of nominal spiked concentration.  The precision of 
the six replicate extracts is also very close at bellow 5% for RSD at both levels.   
This data shows that samples would be stable if defrosted and left at room 
temperature for up to 24 hours and that they could be analysed (and re-frozen 
between analyses) up to four times. 
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Table 18 
Stability of AVP in human plasma stored for 24 hours at room temperature 
  0.75 ng/mL   10 ng/mL 
Replicate observed concentration (ng/mL) 
    
1 0.782  10.5 
2 0.820  10.3 
3 0.764  10.9 
4 0.820  11.4 
5 0.851  10.7 
6 0.773  11.1 
    
mean (ng/mL) 0.802   10.8 
standard deviation (n-1) 0.0339   0.402 
RSD (%) 4.2   3.7 
accuracy (%) 106.9   108.0 
 
 
The data in table 19 shows the concentrations of AVP spiked into human plasma 
compared to the concentrations of AVP determined experimentally in the samples 
frozen for 24 hours then extracted.  The data in table 18 shows that there is good 
accuracy and precision at both the 0.75 and the 10 ng/mL levels, which is indicated 
by the accuracy being within 8% of nominal spiked concentration.  The precision of 
the six replicate extracts is also very close at bellow 5% for RSD at both levels.   
This data shows that samples would be stable if defrosted and left at room 
temperature for up to 24 hours and that they could be analysed (and re-frozen 
between analyses) up to four times. 
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Table 19 
stability of AVP in human plasma following four freeze/thaw cycles 
cycles cycles 
   0.75 ng/mL    10 ng/mL 
 Replicate observed concentration (ng/mL) 
    
1 0.786  9.01 
2 0.758  10.1 
3 0.794  9.53 
4 0.801  10.5 
5 0.806  11.0 
6 0.802  10.9 
    
mean (ng/mL) 0.791   10.2 
standard deviation (n-1) 0.0177   0.786 
RSD (%) 2.2   7.7 
accuracy (%) 105.5   102.0 
 
 
3.2.4 Matrix effects 
The effects human plasma had on AVP and AVP-D5 detection were assessed by 
analysing plasma which was extracted as per section 2.2 then spiked with a solution 
of AVP and AVP-D5 at 5 ng/mL prior to HILIC-UPLC-MS/MS analysis, and 
comparing the results to those obtained from a sample of water extracted as per 
section 2.2  which was spiked with the same AVP : AVP-D5 solution prior to 
analysis.   
 
The results in table 20 show the extent of modification of ionisation response of the 
analyte in the presence of matrix varies very widely, ranging from 85.1 % to 177% 
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enhancement.  This may be caused by the AVP in the absence of matrix adhering to 
the plastic container and therefore giving a lower result than in the presence of 
matrix or may be a genuine reflection of how AVP behaves in human plasma, 
meaning that there may be components in the matrix that alter the detected level of 
AVP by either suppressing or enhancing the signal.  On analysis of unspiked plasma, 
no AVP was detectable.  As these matrix effects are significant, they could seriously 
impact the performance of the study.  
                                                 
5
 There were six blank matrix samples, these are samples of blank matrix from one human plasma 
sample and the six samples are reflective of a population sample.  
Table 20 
Matrix effects – comparison of AVP levels in extracted blank plasma and water samples 
spiked with AVP and AVP-D5 post extraction at 5 ng/mL 
blank matrix 
sample 
number
5
 
 AVP mean peak 
area for post spiked 
water extract (RSD 
%) 
 AVP mean peak area 
for post spiked blank 
plasma extract   
percentage difference 
    
1 46757 127203 172.0 
2 (2.4) 86534 85.1 
3  128228 174.2 
4  122224 161.4 
5  129703 177.4 
6  98142 109.9 
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To compensate for any potential analyte extraction variability, an internal standard 
was used as previously described in chapter 1.  The purpose of including an internal 
standard is to compensate for any variability in the assay including how different 
matrix samples – in this case from different people can affect the AVP levels 
quantified.   
 
When selecting an internal standard, it was important to consider the impact matrix 
effects can have on the experiment.  Analogues of the analyte are often used but do 
not always behave in the same way as the analyte.  One way to account for matrix 
effects is to use a stable isotope labeled-internal standard [18].  
 
The matrix effects for the internal standard were assessed and the results presented 
in table 21.  The results shown in table 21 are consistent with those in table 20 as the 
percentage modification in the presence of unspiked human plasma ranges from 
82.8-170.7% enhancement  
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Figure 41 shows a histogram comparing the percentage modification of AVP and 
AVP-D5 in each of the six plasma samples (from different donors) where close 
correlation of the percentage enhancement experienced by AVP and AVP-D5 in 
human plasma can be seen.  
 
Ionisation suppression or enhancement experienced by the analyte in the matrix will 
also affect the internal standard and therefore be compensated for.  It is also 
important to note that AVP and AVP-D5 co-elute and therefore experience the same 
conditions as one another when they enter the mass spectrometer. 
 
Table 21 
Matrix effects – comparison of AVP-D5 levels in extracted blank plasma and water samples 
spiked with AVP and AVP-D5 post extraction at 5 ng/mL5 ng/mL 
blank matrix 
sample 
number 
 AVP mean peak 
area for post spiked 
water extract (RSD 
%) 
 AVP mean peak area 
for post spiked blank 
plasma extract   
percentage difference 
1 3795131 10075356 165.5 
2 (1.5) 6935912 82.8 
3  10209229 169.0 
4  9915660 161.3 
5  10271622 170.7 
6  7857274 107.0 
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The matrix effects in this study have been assessed and with the use of a stable 
isotope-labelled internal standard do not impact on the integrity of the study as the 
internal standard compensates for the enhancement effects that can be seen for AVP 
in human plasma. 
 
 
Figure 41 – Graph to show the normalisation of matrix enhancement and 
suppression of six samples of human plasma from different donors when AVP 
and AVP-D5 are added post extraction. 
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3.2.5 Selectivity 
In this assay it was important to ensure there were no interferences with the analyte 
peak which is being quantified.  This was achieved by screening six samples of 
blank human plasma from different individuals.  There were no peaks in these 
samples at the retention time of 2.54 minutes for AVP or AVP-D5 which complied 
with the requirement of no blanks exceeding 20% of the LLOQ peak area ratio [16-
18].  A sample chromatogram of an extracted unspiked human plasma sample is 
illustrated in figure 42 
 
Figure 42- XIC for unspiked plasma sample monitoring AVP and AVP-D5 (for 
the transitions 543.4>328.2 and 545.5>328.2) 
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3.2.6 Recovery 
In order to detect the smallest amount of AVP possible, the recovery of AVP was 
calculated.  This was to determine how much was being lost in the extraction.  To do 
this, maximum recovery, assuming no loss of analyte through the extraction was 
calculated for the concentrations 0.75, 5 and 10 ng/mL AVP and solutions of AVP 
and AVP-D5 prepared at these concentrations.  This was added to unspiked plasma 
at the end of the extraction.  The peak area of both AVP and AVP-D5 in these 
samples was compared to the peak area of the extracted AVP spiked frozen plasma 
samples at the levels  0.75, 5 and 10 ng/mL AVP and 5 ng/mL AVP-D5, these are 
shown in  tables 22 and 23. 
 
 Table 22 shows recovery levels of between 55.1 and 67.6%.  This level of recovery 
is not optimal and could be improved which would have a direct effect on the lowest 
limit of AVP which could be detected.  The mean recovery over the levels is 60%.  
This shows consistency in the extraction as all three levels are within 7.5% of the 
mean. 
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The results in table 23 shows that the recovery of the internal standard AVP-D5 is 
55.9%.  This is very close to that of the mean percentage recovery of AVP of 60.1% 
which is shown in table 22.  This result is to be expected as the internal standard is a 
deutertaed form of the analyte, so should behave chemically in the same way 
throughout the extraction as the analyte.  As recovery is consistent throughout the 
concentration range, a recovery value of less than 100% does not impact on the 
study, but will be later suggested as an area of further work.   
 
Table 22 
Percentage of AVP recovered from spiked frozen human plasma extracted as 
per section 2.2 AVP concentration 
(ng/mL) 
mean ak 
area AVP 
(red %) 
mean peak area 
(RSD  %) 
recovery (%) 
0.75 6613.9 11500.1 57.5 
 (24.4) (11.0)  
5 35595.0 64626.0 55.1 
 (12.6) (7.4)  
10 74431.2 110086.6 67.6 
 (11.8) (21.2)  
   
Mean recovery 
(%) 
  60.1 
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3.2.7 Lower limit of quantification 
To assess the lowest amount of AVP which can be quantified using the assay, the 
signal-to-noise ratio of the lowest quantitation standard at the concentration 0.25 
ng/mL was assessed.   A chromatogram for the standard at 0.25 ng/mL is shown in 
figure 43.  The AVP peak (tR = 2.54 min) has an intensity of 1650 (cps) whereas the 
noise has an intensity of 250 (cps), so that the criterion of requiring the signal to 
have better than 5:1 signal: noise ratio [3,4]  is fulfilled as this gives the ratio of 
6.6:1.   
 
Table 23 
recovery of AVP-D5 from human plasma 
AVP-D5 
concentration 
(ng/mL) 
mean peak area 
AVP-D5  (red %) 
mean peak area post 
extraction AVP-D5 
spike (RSD  %) 
recovery (%) 
    
5 52514.3 94027.0 55.9 
 (15.9) (14.9)  
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Figure 43 – XIC (543.4>328.2) for AVP concentration 0.25 ng/mL 
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Chapter 4- Conclusion and further work 
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The aim of this thesis was to develop a bioanalytical assay for the development and 
quantification of the nona-peptide AVP in human plasma at the lowest quantifiable 
limit which can be validated. 
 
In order to achieve these aims a method was developed which explored fractionation 
techniques using both reversed phase and mixed mode ion exchange solid phase 
extraction.  The process of evaluating these included profiling to optimise analyte 
retention and recovery.  The best results in terms of limit detection were using weak 
cation exchange chromatography techniques. 
 
Separation techniques were also investigated in the form of ultra high performance 
liquid chromatography in two different modes – reversed phase and HILIC.  In this 
assessment the lowest detection limits were obtained when using HILIC. 
 
The mass spectrometric techniques used in this method included TurboIonSpray
© 
source for optimal ionisation combined with MRM which utilizes the optimal duty 
cycle.  The ions monitored were [M+2H]
2+
 as the precursor and the y3 for the 
product ion.  Tandem mass spectrometry gave this method selectivity over 
Immunoassays such as ELISA, this is due to the MRM being able to differentiate 
between the analyte and closely related metabolites which is not always possible in 
Immunoassay. 
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A technique interfaced with MS which was trialled was FAIMS.  The aim was to 
investigate if the S:N was improved for the quantitative assay so that a lower LOD 
could be utilised.  The results in chapter 3 show improved S:N at the LLOQ, 
however this was not sufficient enough to lower the LLOQ.  Subsequently FAIMS 
was not used in the final quantitative bioanalytical assay for vasopressin.  
 
The ultimate aim for a bioanalytical method is to ensure it is fit for use in sample 
analysis.  To do this it must be validated.  The validation which took place aimed to 
assess linearity, range, precision, accuracy, matrix effects freeze-thaw stability, room 
temperature stability, short term frozen matrix stability and recovery.  The method 
complied with industry guidelines set out by the FDA, MHRA and EMEA [9-11].  
This method would therefore be suitable for a regulatory bioanalytical study for the 
assessment of AVP in human plasma. 
 
The levels quantified in this method were 0.25 -10 ng/mL.  They do not compete 
with the 1 pg/mL levels that immunoassay offers.  However as a more selective 
technique than immunoassay, with faster set up time, quantitative bioanalysis does 
still have its advantages.  This method meets the requirement of an LLOQ of less 
than 0.5 ng/mL and is subsequently could be used as a screening method for 
elevated biomarker vasopressin levels.  This could be used as a complementary 
technique to immunoassay which can achieve greater sensitivity but less selectivity. 
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Further work to improve this assay should focus on lowering the limit of detection.  
A proposed method for doing this is to improve the fractionation techniques and 
maximise recovery above 60%. 
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